var title_f35_50_36640="Central line dilator";
var content_f35_50_36640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion of soft tissue dilator for central venous catheter placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The soft tissue dilator is advanced over the guidewire using a corkscrew motion. Mild resistance is normal. The dilator does NOT need to be advanced its entire length, but only to the anticipated depth of the vessel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36640=[""].join("\n");
var outline_f35_50_36640=null;
var title_f35_50_36641="Treatment of a leak";
var content_f35_50_36641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Treatment of a surgical leak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The surgical principles in treating a leak include broad spectrum antibiotic coverage, identification and repair of the defect, irrigation and control of contamination, wide external drainage of the contaminated area and gastrostomy tube placement. The drawing depicts a gastrostomy tube that has been placed in the stomach and large drains placed in the area of the leak.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36641=[""].join("\n");
var outline_f35_50_36641=null;
var title_f35_50_36642="Tubal preg yolk sac embryo";
var content_f35_50_36642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tubal pregnancy without cardiac activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal image shows a tubal ring (white arrows) with yolk sac and questionable tiny embryo (red arrow) but no cardiac activity. This patient went on to medical management for ectopic pregnancy.",
"    <div class=\"footnotes\">",
"     U: uterus; O: ovary.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36642=[""].join("\n");
var outline_f35_50_36642=null;
var title_f35_50_36643="MRI hepatocellular CA diagnosis";
var content_f35_50_36643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging (MRI) of hepatocellular cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of the liver performed in a 73-year-old man with hepatitis C and cirrhosis, and a newly diagnosed hepatocellular cancer.",
"    <br>",
"     (A) Axial fast spin-echo T2-weighted MR image shows tumor to be slightly hyperintense, with a thin low-signal intensity capsule (arrow).",
"     <br>",
"      (B) Delayed fat-saturated gadolinium-enhanced axial spin-echo T1-weighted MR image shows the low signal intensity of the tumor relative to adjacent liver, and the capsule is enhancing (arrow).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. Am J Roentgenol 2003; 180:441. Reprinted with permission from the American Journal of Roentgenology. Copyright &copy; 2003 American Roentgen Ray Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36643=[""].join("\n");
var outline_f35_50_36643=null;
var title_f35_50_36644="MRA renal arteries FMD";
var content_f35_50_36644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance angiography of the renal arteries in FMD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An MRA image using 3D maximum intensity projection technique (A) and an abdominal aortogram (B) display the abdominal aorta and renal arteries in the AP projection. There is bilateral beading of the renal arteries (red arrows) consistent with a diagnosis of fibromuscular dysplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hesham Malik, MD and Dmitry J Rabkin, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36644=[""].join("\n");
var outline_f35_50_36644=null;
var title_f35_50_36645="Brompheniramine and pseudoephedrine: Drug information";
var content_f35_50_36645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brompheniramine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/18/38180?source=see_link\">",
"    see \"Brompheniramine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15909?source=see_link\">",
"    see \"Brompheniramine and pseudoephedrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brotapp [OTC];",
"     </li>",
"     <li>",
"      J-Tan D PD [OTC];",
"     </li>",
"     <li>",
"      Lodrane&reg; D [OTC];",
"     </li>",
"     <li>",
"      LoHist PSB [OTC];",
"     </li>",
"     <li>",
"      Q-Tapp Cold &amp; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rhinitis and nasal congestion:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Brompheniramine 4 mg and pseudoephedrine 60 mg: One capsule every 4-6 hours (maximum: 4 capsules/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 1 mg and pseudoephedrine 15 mg per 5 mL: 20 mL every 6 hours (maximum: 80 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 4 mg and pseudoephedrine 20 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15909?source=see_link\">",
"      see \"Brompheniramine and pseudoephedrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rhinitis and nasal congestion:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 1 mg and pseudoephedrine 7.5 mg per 1 mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2 to &lt;6 years: 1 mL every 4-6 hours (maximum: 6 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-12 years: 2 mL every 4-6 hours (maximum: 12 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 1 mg and pseudoephedrine 15 mg per 5 mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years: 10 mL every 6 hours (maximum: 40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brompheniramine 4 mg and pseudoephedrine 20 mg per 5 mL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F142682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lodrane&reg; D: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Brotapp: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (120 mL, 240 mL, 480 mL) [ethanol free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     LoHist PSB: Brompheniramine maleate 4 mg and pseudoephedrine hydrochloride 20 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Q-Tapp Cold &amp; Allergy: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 15 mg per 5 mL (118 mL, 237 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     J-Tan D PD: Brompheniramine maleate 1 mg and pseudoephedrine hydrochloride 7.5 mg per 1 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; cotton candy flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms associated with seasonal and perennial allergic rhinitis, the common cold, or sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, flushing, hypertension, pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, CNS stimulation, dizziness, excitability (children; rare), giddiness, hallucinations, headache, insomnia, irritability, lassitude, nervousness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention (with BPH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular skeletal: Tremors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory difficulty",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity  to brompheniramine, pseudoephedrine, or any component of the formulation; concomitant MAO inhibitor therapy (or 2 weeks following MAO inhibitor use)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution or avoid in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F142677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effect.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13713949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lodrane D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-60 mg (60): $36.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Q-Tapp Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-15 mg/5 mL (118 mL): $4.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Brotapp Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-15 mg/5 mL (237 mL): $7.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (BroveX PSB Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-20 mg/5 mL (473 mL): $187.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (J-Tan D PD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-7.5 mg/mL (30 mL): $69.66",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5549430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dimetapp (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brompheniramine maleate is an antihistamine with H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor activity; pseudoephedrine, a sympathomimetic amine and isomer of ephedrine, acts as a decongestant in respiratory tract mucous membranes with less vasoconstrictor action than ephedrine in normotensive individuals.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8820 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36645=[""].join("\n");
var outline_f35_50_36645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142680\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142691\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142681\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142688\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142682\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142666\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142689\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142670\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142657\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298891\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142677\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13713949\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323025\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5549430\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142656\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142669\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/18/38180?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15909?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_50_36646="Clinical manifestations of hypocalcemia";
var content_f35_50_36646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hypocalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     David Goltzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36646/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/50/36646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia may be associated with a spectrum of clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef62347 \" href=\"mobipreview.htm?39/62/40939\">",
"     table 1",
"    </a>",
"    ), ranging from few if any symptoms if the hypocalcemia is mild, to life-threatening seizures, refractory heart failure, or laryngospasm if it is severe. In addition to severity, the rate of development of hypocalcemia and chronicity determine the clinical manifestations.",
"   </p>",
"   <p>",
"    Among the symptoms of hypocalcemia, tetany, papilledema, and seizures may occur in patients who develop hypocalcemia acutely. By comparison, ectodermal and dental changes, cataracts, basal ganglia calcification, and extrapyramidal disorders are features of chronic hypocalcemia. These last findings are most common in patients with hypoparathyroidism.",
"   </p>",
"   <p>",
"    The clinical manifestations of hypocalcemia are discussed here. The etiology of, diagnostic approach to, and the treatment of hypocalcemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34005?source=see_link\">",
"     \"Diagnostic approach to hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of acute hypocalcemia is tetany, which is characterized by neuromuscular irritability. The symptoms of tetany may be mild (peri-oral numbness, paresthesias of the hands and feet, muscle cramps) or severe (carpopedal spasm, laryngospasm, and focal or generalized seizures, which must be distinguished from the generalized tonic muscle contractions that occur in severe tetany). Other patients have less specific symptoms such as fatigue, hyperirritability, anxiety, and depression, and some patients, even with severe hypocalcemia, have no neuromuscular symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tetany",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hypocalcemia directly increases peripheral neuromuscular irritability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/1\">",
"     1",
"    </a>",
"    ]. As measured electromyographically, tetany consists of repetitive high-frequency discharges after a single stimulus. Hyperexcitability of peripheral neurons is probably the most important pathophysiologic effect of hypocalcemia, but hyperexcitability occurs at all levels of the nervous system, including motor end-plates, the spinal reflexes, and the central nervous system.",
"   </p>",
"   <p>",
"    Tetany is uncommon unless the serum ionized calcium concentration falls below 4.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which usually corresponds to a serum total calcium concentration of 7.0 to 7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8 to 1.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Patients in whom the onset of hypocalcemia is gradual tend to have fewer symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that determine the variation in frequency and severity of symptoms include acid-base status, hypomagnesemia, and potassium balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link&amp;anchor=H4#H4\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Bone and calcium metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocalcemia and alkalosis act synergistically to cause tetany. Although alkalosis can directly reduce serum ionized calcium, the ability of alkalosis to enhance tetany is only partly due to this effect since the decrease is relatively small. Respiratory alkalosis alone (eg, hyperventilation) can cause tetany, even in the absence of underlying hypocalcemia. By contrast, tetany is unusual among patients with chronic renal failure and hypocalcemia (occasionally severe) because of the protective effect of concurrent metabolic acidosis.",
"   </p>",
"   <p>",
"    Tetany is manifested clinically by both sensory and muscular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms typically begin with peri-oral and acral paresthesias. These symptoms can cause hyperventilation, leading to respiratory alkalosis and an elevation in arterial pH, which in turn exacerbate the paresthesias.",
"     </li>",
"     <li>",
"      The motor symptoms of tetany include stiffness and clumsiness, myalgia, and muscle spasms and cramps. In the hands, the result is forced adduction of the thumb, flexion of the metacarpophalangeal joints and wrists, and extension of the fingers (carpopedal spasm). Spasm of the respiratory muscles and of the glottis (laryngismus stridulus) can cause cyanosis.",
"     </li>",
"     <li>",
"      Autonomic manifestations include diaphoresis, bronchospasm, and biliary colic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classic physical findings in patients with neuromuscular irritability due to latent tetany are Trousseau's and Chvostek's signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Trousseau's sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trousseau's sign is the induction of carpopedal spasm by inflation of a sphygmomanometer above systolic blood pressure for three minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Carpopedal spasm, as indicated above, is characterized by adduction of the thumb, flexion of the metacarpophalangeal joints, extension of the interphalangeal joints, and flexion of the wrist. It may also be induced by voluntary hyperventilation for one to two minutes after release of the cuff.",
"   </p>",
"   <p>",
"    Trousseau's sign depends upon the effect of ischemia to increase excitability of the nerve trunk under the cuff, rather than at the motor end-plate; excitability is maximal at three minutes and returns to normal even if ischemia is maintained for a longer period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chvostek's sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chvostek's sign is contraction of the ipsilateral facial muscles elicited by tapping the facial nerve just anterior to the ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/5\">",
"     5",
"    </a>",
"    ]. The response ranges from twitching of the lip to spasm of all facial muscles and depends upon the severity of the hypocalcemia. Chvostek's sign occurs in about 10 percent of normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Trousseau's sign is more specific than Chvostek's sign, both may be negative in patients with hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grand mal, petit mal, and focal seizures can occur in hypocalcemia, and may be the sole presenting symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. The presence of seizures without tetany in patients with hypocalcemia may be explained by the observation that low cerebrospinal fluid ionized calcium concentrations may have a convulsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/9\">",
"     9",
"    </a>",
"    ] but not a direct tetanic effect. In patients with seizures caused by hypocalcemia the EEG shows both spikes (\"convulsive effect\") and bursts of high-voltage paroxysmal slow waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension may complicate acute hypocalcemia, particularly when rapidly induced either by EDTA or transfusion of citrated blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In addition, decreased myocardial performance and even congestive heart failure (with or without hypotension) have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Myocardial dysfunction is reversible with calcium repletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Although the mechanism is undefined, calcium plays a critical role in excitation-contraction coupling and is required for epinephrine-induced glycogenolysis in the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocalcemia characteristically causes prolongation of the QT interval in the electrocardiogram (",
"    <a class=\"graphic graphic_waveform graphicRef66206 \" href=\"mobipreview.htm?27/17/27926\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Hypocalcemia prolongs phase 2 of the action potential with the impact modulated by the rate of change of serum calcium concentration and function of the myocyte calcium channels. Prolongation of the QT interval is associated with early after-repolarizations and triggered dysrhythmias. Torsades de pointes (polymorphic ventricular tachycardia associated with a prolonged QT interval) can potentially be triggered by hypocalcemia but is much less common than with hypokalemia or hypomagnesemia. Although electrocardiographic conduction abnormalities are common, serious hypocalcemia-induced dysrhythmias, such as heart block and ventricular dysrhythmias, are infrequent.",
"   </p>",
"   <p>",
"    Hypocalcemia can also cause insensitivity to digitalis, an effect opposite to that of hypercalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Papilledema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papilledema can occur in patients with hypocalcemia of any cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. It occurs only when hypocalcemia is severe, and it usually improves with reversal of hypocalcemia. It may or may not be accompanied by high cerebrospinal fluid pressure (benign intracranial hypertension). Rarely, optic neuritis (distinguished by decreased visual activity) rather than papilledema is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychiatric manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia can cause psychological symptoms, particularly emotional instability, anxiety, and depression. Less common are confusional states, hallucinations, and frank psychosis. All are reversible with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DISEASE SPECIFIC MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypoparathyroidism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Extrapyramidal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal ganglia calcifications are a manifestation of long standing hypoparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. They can be detected by computed tomography when routine skull x-rays are normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/28\">",
"     28",
"    </a>",
"    ]. Some patients with basal ganglia calcifications develop parkinsonism, other movement disorders (dystonia, hemiballismus, choreoathetosis, and oculogyric crises), or dementia, while others remain asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. In some cases, extrapyramidal symptoms improve after treatment with vitamin D and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/26,30\">",
"     26,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ocular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypocalcemia, particularly when due to hypoparathyroidism, causes cataracts, and treatment of hypocalcemia arrests their progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Keratoconjunctivitis has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Skeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with several hypocalcemic disorders have skeletal abnormalities, such findings do not appear to be direct consequences of hypocalcemia, but rather are related to the underlying disease. Patients with hypoparathyroidism have variable skeletal abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with idiopathic or postsurgical hypoparathyroidism may have increased bone mineral density as compared with normal subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with congenital hypoparathyroid syndromes may have osteosclerosis, cortical thickening, and craniofacial abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology of hypocalcemia in infants and children\", section on 'Genetic'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dental abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental abnormalities occur when hypocalcemia is present during early development. They include dental hypoplasia, failure of tooth eruption, defective enamel and root formation, and abraded carious teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/33,37\">",
"     33,37",
"    </a>",
"    ]. Early treatment of hypocalcemia can reverse these changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ectodermal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic hypocalcemia, the skin is dry, puffy, and coarse. Other dermatologic manifestations of chronic hypocalcemia include course, brittle, and sparse hair with patchy alopecia, and brittle nails, with characteristic transverse grooves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36646/abstract/33\">",
"     33",
"    </a>",
"    ]. These abnormalities correlate with the severity and chronicity of hypocalcemia and are reversible with restoration of normocalcemia.",
"   </p>",
"   <p>",
"    Moniliasis occurs only in patients with idiopathic hypoparathyroidism, usually as a component of polyglandular autoimmune syndrome type 1, which is characterized by mutations in the autoimmune regulator (AIRE) gene and may be sporadic or inherited as an autosomal recessive disorder. This disorder is associated with defective cellular immunity that persists despite correction of hypocalcemia. The nails, skin, and the gastrointestinal tract are typically involved. The moniliasis is often refractory to antifungal therapy. Other associated clinical manifestations of polyglandular autoimmune syndrome type 1 include those of adrenal insufficiency and, less frequently, those of other autoimmune disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1645701\">",
"    <span class=\"h3\">",
"     Renal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalciuria is a feature of all hypocalcemic states due to a decreased filtered load. Urinary calcium excretion is relatively high in patients with hypoparathyroidism, because of loss of the stimulatory effect of PTH on renal tubular calcium reabsorption. Therefore frank hypercalciuria can occur as the serum calcium concentration is raised toward normal, and concern about hypercalciuria and possible nephrolithiasis may prevent full correction of hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypocalcemia\", section on 'Preventing hypercalciuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pseudohypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoparathyroidism (PHP) refers to a group of heterogeneous disorders defined by targeted organ (kidney) unresponsiveness to PTH and characterized biochemically by hypocalcemia and hyperphosphatemia with elevated PTH concentrations. There are several subtypes of PHP, based upon genetic and clinical characteristics. Some variants of PHP are associated with skeletal abnormalities, intellectual impairment, and resistance to other hormones. Pseudohypoparathyroidism is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology of hypocalcemia in infants and children\", section on 'End-organ resistance/pseudohypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency or resistance can cause hypocalcemia and, if severe, lead to rickets and osteomalacia. Osteomalacia may be asymptomatic and present radiologically as osteopenia. It can also produce characteristic symptoms including diffuse bone pain and tenderness and muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the classic radiographic signs of vitamin D deficiency rickets, children may have muscle weakness and hypotonia, motor retardation, and stunted growth. Children with hereditary vitamin D-resistant rickets may also have alopecia, multiple milia, epidermal cysts, and oligodontia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link&amp;anchor=H24#H24\">",
"     \"Causes of vitamin D deficiency and resistance\", section on 'Vitamin D resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of rickets in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/18/6434?source=see_link\">",
"       \"Patient information: Hypoparathyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of hypocalcemia depend upon the severity and chronicity of hypocalcemia (",
"      <a class=\"graphic graphic_table graphicRef62347 \" href=\"mobipreview.htm?39/62/40939\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of acute hypocalcemia are characterized by neuromuscular irritability or tetany. Symptoms range from mild paresthesias to carpopedal spasm to seizures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic hypocalcemia from hypoparathyroidism may be associated with cataract formation, ectopic calcification (basal ganglia), and occasionally parkinsonism and dementia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hypoparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/1\">",
"      Macefield G, Burke D. Paraesthesiae and tetany induced by voluntary hyperventilation. Increased excitability of human cutaneous and motor axons. Brain 1991; 114 ( Pt 1B):527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/2\">",
"      Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/3\">",
"      Navarro J, Oster JR, Gkonos PJ, et al. Tetany induced on separate occasions by administration of potassium and magnesium in a patient with hungry-bone syndrome. Miner Electrolyte Metab 1991; 17:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/4\">",
"      Cohen L. Potassium replacement associated with the development of tetany in a patient with hypomagnesaemia. Magnes Res 1993; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/5\">",
"      Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/6\">",
"      Thakker, RV. Hypocalcemia: Pathogenesis, differential diagnosis, and management. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society of Bone and Mineral Research, sixth edition 2006; 35:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/7\">",
"      Armelisasso C, Vaccario ML, Pontecorvi A, Mazza S. Tonic-clonic seizures in a patient with primary hypoparathyroidism: a case report. Clin EEG Neurosci 2004; 35:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/8\">",
"      Mrowka M, Knake S, Klinge H, et al. Hypocalcemic generalised seizures as a manifestation of iatrogenic hypoparathyroidism months to years after thyroid surgery. Epileptic Disord 2004; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/9\">",
"      Zuckermann EC, Glaser GH. Anticonvulsive action of increased calcium concentration in cerebrospinal fluid. Arch Neurol 1973; 29:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/10\">",
"      Swash M, Rowan AJ. Electroencephalographic criteria of hypocalcemia and hypercalcemia. Arch Neurol 1972; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/11\">",
"      Denlinger JK, Nahrwold ML. Cardiac failure associated with hypocalcemia. Anesth Analg 1976; 55:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/12\">",
"      Ghent S, Judson MA, Rosansky SJ. Refractory hypotension associated with hypocalcemia and renal disease. Am J Kidney Dis 1994; 23:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/13\">",
"      Shinoda T, Aizawa T, Shirota T, et al. Exacerbation of latent heart failure by mild hypocalcemia after parathyroidectomy in a long-term hemodialysis patient. Nephron 1992; 60:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/14\">",
"      Kazmi AS, Wall BM. Reversible congestive heart failure related to profound hypocalcemia secondary to hypoparathyroidism. Am J Med Sci 2007; 333:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/15\">",
"      Levine SN, Rheams CN. Hypocalcemic heart failure. Am J Med 1985; 78:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/16\">",
"      Wong CK, Lau CP, Cheng CH, et al. Hypocalcemic myocardial dysfunction: short- and long-term improvement with calcium replacement. Am Heart J 1990; 120:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/17\">",
"      Kudoh C, Tanaka S, Marusaki S, et al. Hypocalcemic cardiomyopathy in a patient with idiopathic hypoparathyroidism. Intern Med 1992; 31:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/18\">",
"      Brunvand L, H&aring;g&aring; P, Tangsrud SE, Haug E. Congestive heart failure caused by vitamin D deficiency? Acta Paediatr 1995; 84:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/19\">",
"      Rimailho A, Bouchard P, Schaison G, et al. Improvement of hypocalcemic cardiomyopathy by correction of serum calcium level. Am Heart J 1985; 109:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/20\">",
"      Benoit SR, Mendelsohn AB, Nourjah P, et al. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005; 12:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/21\">",
"      Meyer T, Ruppert V, Karatolios K, Maisch B. Hereditary long QT syndrome due to autoimmune hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. J Electrocardiol 2007; 40:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/22\">",
"      Chopra D, Janson P, Sawin CT. Insensitivity to digoxin associated with hypocalcemia. N Engl J Med 1977; 296:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/23\">",
"      Bajandas FJ, Smith JL. Optic nueritis in hypoparathyroidism. Neurology 1976; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/24\">",
"      Sheldon RS, Becker WJ, Hanley DA, Culver RL. Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association. Can J Neurol Sci 1987; 14:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/25\">",
"      Hochman HI, Mejlszenkier JD. Cataracts and pseudotumor cerebri in an infant with vitamin D-deficiency rickets. J Pediatr 1977; 90:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/26\">",
"      Tambyah PA, Ong BK, Lee KO. Reversible parkinsonism and asymptomatic hypocalcemia with basal ganglia calcification from hypoparathyroidism 26 years after thyroid surgery. Am J Med 1993; 94:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/27\">",
"      Rastogi R, Beauchamp NJ, Ladenson PW. Calcification of the basal ganglia in chronic hypoparathyroidism. J Clin Endocrinol Metab 2003; 88:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/28\">",
"      Illum F, Dupont E. Prevalences of CT-detected calcification in the basal ganglia in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neuroradiology 1985; 27:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/29\">",
"      Preusser M, Kitzwoegerer M, Budka H, Brugger S. Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism. Neuropathology 2007; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/30\">",
"      Abe S, Tojo K, Ichida K, et al. A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Intern Med 1996; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/31\">",
"      Rajendram R, Deane JA, Barnes M, et al. Rapid onset childhood cataracts leading to the diagnosis of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Am J Ophthalmol 2003; 136:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/32\">",
"      Stein R, Godel V. Hypocalcemic cataract. J Pediatr Ophthalmol Strabismus 1980; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/33\">",
"      Goltzman, D, Cole, DEC. Hypoparathyroidism. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, American Society of Bone and Mineral Research, 6th edition 2006; 36:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/34\">",
"      Merenmies L, Tarkkanen A. Chronic bilateral keratitis in autoimmune polyendocrinopathy-candidiadis-ectodermal dystrophy (APECED). A long-term follow-up and visual prognosis. Acta Ophthalmol Scand 2000; 78:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/35\">",
"      Laway BA, Goswami R, Singh N, et al. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 2006; 64:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/36\">",
"      Chan FK, Tiu SC, Choi KL, et al. Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 2003; 88:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36646/abstract/37\">",
"      Kinirons MJ, Glasgow JF. The chronology of dentinal defects related to medical findings in hypoparathyroidism. J Dent 1985; 13:346.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 833 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36646=[""].join("\n");
var outline_f35_50_36646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tetany",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Trousseau's sign",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chvostek's sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychiatric manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DISEASE SPECIFIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Extrapyramidal disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ocular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Skeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dental abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ectodermal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1645701\">",
"      - Renal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pseudohypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/833|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/62/40939\" title=\"table 1\">",
"      Clin manif hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/833|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?27/17/27926\" title=\"waveform 1\">",
"      Prolonged QT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34005?source=related_link\">",
"      Diagnostic approach to hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/18/6434?source=related_link\">",
"      Patient information: Hypoparathyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_50_36647="Malaria life cycle";
var content_f35_50_36647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Plasmodium life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 579px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1. Plasmodium-infected Anopheles mosquito bites a human and transmits sporozoites into the bloodstream. 2. Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (pre-erythrocytic stage). 3. Hypnozoites are a quiescent stage in the liver that exist only in the setting of P. vivax and P. ovale infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late onset or relapsed disease can occur up to many months after initial infection. 4. The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). 5. Some merozoites differentiate into male or female gametocytes. These cells are ingested by the Anopheles mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36647=[""].join("\n");
var outline_f35_50_36647=null;
var title_f35_50_36648="Digital myxoid cyst";
var content_f35_50_36648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85602%7EDERM%2F85603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85602%7EDERM%2F85603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital myxoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Longitudinal depression of the nail plate caused by a digital myxoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36648=[""].join("\n");
var outline_f35_50_36648=null;
var title_f35_50_36649="Indomethacin: Drug information";
var content_f35_50_36649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indomethacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/34/550?source=see_link\">",
"    see \"Indomethacin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"    see \"Indomethacin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Indocin&reg;;",
"     </li>",
"     <li>",
"      Indocin&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Indomethacin&reg;;",
"     </li>",
"     <li>",
"      Indocid&reg; P.D.A.;",
"     </li>",
"     <li>",
"      Novo-Methacin;",
"     </li>",
"     <li>",
"      Nu-Indo;",
"     </li>",
"     <li>",
"      Pro-Indo;",
"     </li>",
"     <li>",
"      ratio-Indomethacin;",
"     </li>",
"     <li>",
"      Sandoz-Indomethacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory/rheumatoid disorders",
"     </b>",
"     (use lowest effective dose): Oral, rectal: 25-50 mg/dose 2-3 times/day; maximum dose: 200 mg/day; extended release capsule should be given on a 1-2 times/day schedule (maximum dose for extended release: 150 mg/day). In patients with arthritis and persistent night pain and/or morning stiffness, may give the larger portion (up to 100 mg) of the total daily dose at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bursitis/tendonitis:",
"     </b>",
"     Oral, rectal: Initial dose: 75-150 mg/day in 3-4 divided doses",
"     <b>",
"      or",
"     </b>",
"     1-2 divided doses for extended release; usual treatment is 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute gouty arthritis:",
"     </b>",
"     Oral, rectal: 50 mg 3 times daily until pain is tolerable then reduce dose; usual treatment &lt;3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP) (unlabeled use):",
"     </b>",
"     Rectal: 100 mg immediately after ERCP (Elmunzer, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"      see \"Indomethacin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patent ductus arteriosus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: I.V.: Initial: 0.2 mg/kg, followed by 2 doses depending on postnatal age (PNA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      PNA at time of FIRST dose &lt;48 hours:",
"     </i>",
"     0.1 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      PNA at time of FIRST dose 2-7 days:",
"     </i>",
"     0.2 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      PNA at time of FIRST dose &gt;7 days:",
"     </i>",
"     0.25 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, may use 12-hour dosing interval if urine output &gt;1 mL/kg/hour after prior dose; use 24-hour dosing interval if urine output is &lt;1 mL/kg/hour but &gt;0.6 mL/kg/hour; doses should be withheld if patient has oliguria (urine output &lt;0.6 mL/kg/hour) or anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory/rheumatoid disorders",
"     </b>",
"     (use lowest effective dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years: Oral: 1-2 mg/kg/day in 2-4 divided doses; maximum dose: 4 mg/kg/day; not to exceed 150-200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;14 years: Oral, rectal: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use lowest recommended dose and frequency in elderly to initiate therapy for indications listed in adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2532858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; not recommended in patients with advanced renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14211453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg; I.V.: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg;: 50 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg;: 25 mg/5 mL (237 mL) [contains ethanol 1%; pineapple-coconut-mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral suspension, suppository",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088612.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088612.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food, milk, or antacids to decrease GI adverse effects. Extended release capsules must be swallowed whole; do not crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer over 20-30 minutes. Reconstitute I.V. formulation just prior to administration; discard any unused portion; avoid I.V. bolus administration or infusion via an umbilical catheter into vessels near the superior mesenteric artery as these may cause vasoconstriction and can compromise blood flow to the intestines. Do not administer intra-arterially.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Furosemide, insulin (regular), nitroprusside, potassium chloride, sodium bicarbonate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amino acid injection, calcium gluconate, cimetidine, dobutamine, dopamine, gentamicin, levofloxacin, pantoprazole, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dextrose injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute gouty arthritis, acute bursitis/tendonitis, moderate-to-severe osteoarthritis, rheumatoid arthritis, ankylosing spondylitis; I.V. form used as alternative to surgery for closure of patent ductus arteriosus in neonates",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7688405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of preterm labor; prevention of pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Indocin&reg; may be confused with Imodium&reg;, Lincocin&reg;, Minocin&reg;, Vicodin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 9%), depression (&lt;3%), fatigue (&lt;3%), malaise (&lt;3%), somnolence (&lt;3%), vertigo (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3% to 9%), epigastric pain (3% to 9%), heartburn (3% to 9%), indigestion (3% to 9%), nausea (3% to 9%), abdominal pain/cramps/distress (&lt;3%), constipation (&lt;3%), diarrhea (&lt;3%), rectal irritation (suppository), tenesmus (suppository), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress, agranulocytosis, allergic rhinitis, anaphylaxis, anemia, angiitis, angioedema, aplastic anemia, arrhythmia, aseptic meningitis, asthma, bone marrow suppression, bronchospasm,  chest pain, cholestatic jaundice, coma, confusion, CHF, cystitis, depersonalization, depression, diplopia, disseminated intravascular coagulation (DIC), dysarthria, dyspnea, ecchymosis, edema, epistaxis, erythema multiforme, erythema nodosum, exfoliative dermatitis, fluid retention, flushing, hair loss, gastric perforation (rare), gastritis, GI bleeding, GI ulceration, glucosuria, gynecomastia, hearing decreased, hematuria, hemolytic anemia, hepatitis (including fatal cases), hot flashes, hyperglycemia, hyperkalemia, hypersensitivity reactions, hyper-/hypotension, interstitial nephritis, intestinal strictures,  involuntary muscle movements, leukopenia, lightheadedness, necrotizing fasciitis, nephrotic syndrome, oliguria, paresthesia, parkinson&rsquo;s exacerbation, peptic ulcer, peripheral neuropathy, proctitis, psychosis, pulmonary edema,  purpura, rectal bleeding, renal insufficiency, renal failure, retinal/macular disturbances, seizure exacerbation, shock, somnolence, Stevens-Johnson syndrome, stomatitis, syncope, thrombocytopenia, thrombocytopenic purpura, thrombophlebitis, toxic amblyopia, toxic epidermal necrolysis, ulcerative stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indomethacin, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; patients with a history of proctitis or recent rectal bleeding (suppositories)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates: Necrotizing enterocolitis;  impaired renal function; active bleeding (including intracranial hemorrhage and gastrointestinal bleeding), thrombocytopenia, coagulation defects; untreated infection; congenital heart disease where patent ductus arteriosus is necessary",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Prolonged use may cause corneal deposits and retinal disturbances; discontinue if visual changes are observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution with depression; use may aggravate depression or other psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; use may aggravate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinsonism: Use caution with Parkinson&rsquo;s disease; use may aggravate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). Risk of adverse events may be higher with indomethacin compared to other NSAIDs; avoid use in this age group (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Oral: Safety and efficacy have not been established in children &lt;14 years of age. Hepatotoxicity has been reported in younger children treated for juvenile idiopathic arthritis (JIA). Closely monitor if needed in children &ge;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F182702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Indomethacin may increase the serum concentration of Tiludronate.  Management: Separate doses of tiludronate at least two hours before or two hours after indomethacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamterene: Indomethacin may enhance the nephrotoxic effect of Triamterene.  Management: Consider alternatives to concomitant treatment with triamterene and indomethacin.  If the combination cannot be avoided, monitor for development of renal failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F182652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease the rate but not the extent of absorption. Indomethacin peak serum levels may be delayed if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7688406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies indomethacin as pregnancy category C. Indomethacin crosses the placenta and can be detected in fetal plasma and amniotic fluid. Indomethacin exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester, including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, failure of the ductus arteriosus to close postnatally, and fetal tricuspid regurgitation; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; and pulmonary hypertension. The risk of fetal ductal constriction following maternal use of indomethacin is increased with gestational age and duration of therapy. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Indomethacin has been used in the management of preterm labor. Indomethacin should be used with caution in pregnant women with hypertension. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7688408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indomethacin is excreted into breast milk and low amounts have been measured in the plasma of nursing infants. Seizures in a nursing infant were observed in one case report, although adverse events have not been noted in other cases. Breast-feeding is not recommended by the manufacturer. (The therapeutic use of indomethacin is contraindicated in neonates with significant renal failure.)  Hypertensive crisis and psychiatric side effects have been noted in case reports following use of indomethacin for analgesia in postpartum women. Use with caution in nursing women with hypertensive disorders of pregnancy or pre-existing renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F182639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause GI upset; take with food or milk to minimize",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F182638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Indomethacin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (60): $180.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Indomethacin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $38.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $63.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Indocin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $642.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Indomethacin Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $551.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Indocin Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $340.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Indocin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (237 mL): $256.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F182627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (serum creatinine, BUN); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation, CBC, liver function tests (particularly with pediatric use); ophthalmologic exams with prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agilex (AR);",
"     </li>",
"     <li>",
"      Amuno Retard (DE);",
"     </li>",
"     <li>",
"      Andocit (TH);",
"     </li>",
"     <li>",
"      Anodyne (TW);",
"     </li>",
"     <li>",
"      Antalgin (MX);",
"     </li>",
"     <li>",
"      Areumatin (ID);",
"     </li>",
"     <li>",
"      Argilex (AR);",
"     </li>",
"     <li>",
"      Arthrexin (AU, ZA);",
"     </li>",
"     <li>",
"      Artrilona S (UY);",
"     </li>",
"     <li>",
"      Asimet (MY);",
"     </li>",
"     <li>",
"      Catlep (JP);",
"     </li>",
"     <li>",
"      Chrono-Indocid (FR);",
"     </li>",
"     <li>",
"      Confortid (AE, BH, CY, DK, EG, FI, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Docin (TH);",
"     </li>",
"     <li>",
"      Dolazal (NL);",
"     </li>",
"     <li>",
"      Dometin (NL);",
"     </li>",
"     <li>",
"      Elmego Spray (TH);",
"     </li>",
"     <li>",
"      Elmetacin (EC);",
"     </li>",
"     <li>",
"      Elmetacin Topical (NZ);",
"     </li>",
"     <li>",
"      Flamaret (ZA);",
"     </li>",
"     <li>",
"      IDC (TH);",
"     </li>",
"     <li>",
"      Idicin (IN);",
"     </li>",
"     <li>",
"      IM-75 (AR);",
"     </li>",
"     <li>",
"      Imet (BF, BJ, CI, ET, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Indacin (PK);",
"     </li>",
"     <li>",
"      Indaflex (MX);",
"     </li>",
"     <li>",
"      Indalgin (TW);",
"     </li>",
"     <li>",
"      Indanet (MX);",
"     </li>",
"     <li>",
"      Indecin (TW);",
"     </li>",
"     <li>",
"      Indo (MY, SG);",
"     </li>",
"     <li>",
"      Indocap (IN);",
"     </li>",
"     <li>",
"      Indocap S.R. (IN);",
"     </li>",
"     <li>",
"      Indocid (AE, AT, AU, BB, BE, BF, BH, BJ, BR, BS, BZ, CH, CI, CY, EG, ET, FR, GH, GM, GN, GR, HK, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, OM, PE, PH, QA, SA, SC, SD, SL, SN, SY, TN, TT, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Indocid-R (NZ);",
"     </li>",
"     <li>",
"      Indocin I.V. (IL, KP);",
"     </li>",
"     <li>",
"      Indocolir (DE);",
"     </li>",
"     <li>",
"      Indocollyre (FR, HK, IL);",
"     </li>",
"     <li>",
"      Indocontin (CL);",
"     </li>",
"     <li>",
"      Indogesic (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Indolag (AE, BF, BH, BJ, BM, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Indolgina (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Indomecin (CO);",
"     </li>",
"     <li>",
"      Indomed F (TH);",
"     </li>",
"     <li>",
"      Indomee (SE);",
"     </li>",
"     <li>",
"      Indomelan (AT);",
"     </li>",
"     <li>",
"      Indomen (SG);",
"     </li>",
"     <li>",
"      Indomet (EE);",
"     </li>",
"     <li>",
"      Indometin (FI);",
"     </li>",
"     <li>",
"      Indomin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, RU, SA, SY, YE);",
"     </li>",
"     <li>",
"      Indono (TH);",
"     </li>",
"     <li>",
"      Indorem (BM, GY, PR, SR);",
"     </li>",
"     <li>",
"      Indosan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Indosima (PY);",
"     </li>",
"     <li>",
"      Indovis (IL);",
"     </li>",
"     <li>",
"      Indoxen (HK);",
"     </li>",
"     <li>",
"      Indoy (TW);",
"     </li>",
"     <li>",
"      Indrenin (CZ);",
"     </li>",
"     <li>",
"      Indylon (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Inomet (TR);",
"     </li>",
"     <li>",
"      Malival (MX);",
"     </li>",
"     <li>",
"      Metacen (IT);",
"     </li>",
"     <li>",
"      Methacin (MY);",
"     </li>",
"     <li>",
"      Metindol (CZ, PL);",
"     </li>",
"     <li>",
"      Reumacid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Rheumacid (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Stratasin (MX);",
"     </li>",
"     <li>",
"      Vi-Gel (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Immediate release: Prompt and extensive; Extended release: 90% over 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.34-1.57 L/kg; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; significant enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4.5 hours; prolonged in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Immediate release: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (60%, primarily as glucuronide conjugates); feces (33%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bilimoria Y, Moy J, and Yu B, &ldquo;Nephrotic Syndrome, Exfoliative Dermatitis, Eosinophilia, and Elevated IgE Associated With Indomethacin,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 95(2):287.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coombs RC, Morgan ME, Durbin GM, et al, &ldquo;Gut Blood Flow Velocities in the Newborn: Effects of Patent Ductus Arteriosus and Parenteral Indomethacin,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1990, 65(10 Spec No):1067-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2241229/pubmed\" id=\"2241229\" target=\"_blank\">",
"        2241229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elmunzer BJ, Scheiman JM, Lehman GA, et al, &ldquo;A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(15):1414-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/22494121/pubmed\" id=\"22494121\" target=\"_blank\">",
"        22494121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersony WM, Peckham GJ, Ellison RC, et al, &ldquo;Effects of Indomethacin in Premature Infants With Patent Ductus Arteriosus: Results of a National Collaborative Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(6):895-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/6343572/pubmed\" id=\"6343572\" target=\"_blank\">",
"        6343572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolinske SC, Hall AH, Vandenberg SA, et al, &ldquo;Toxic Effects of Nonsteroid Anti-inflammatory Drugs in Overdose. An Overview of Recent Evidence on Clinical Effects and Dose-Response Relationships,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(4):252-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2198051/pubmed\" id=\"2198051\" target=\"_blank\">",
"        2198051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The International Agranulocytosis and Aplastic Anemia Study, &ldquo;Risks of Agranulocytosis and Aplastic Anemia. A First Report of Their Relation to Drug Use With Special Reference to Analgesics,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1986, 256(13):1749-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/3747087/pubmed\" id=\"3747087\" target=\"_blank\">",
"        3747087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong F, Massie D, and Hsu P, &ldquo;The Effect of Misoprostol on Indomethacin-Induced Renal Dysfunction in Well-Compensated Cirrhosis,&rdquo;",
"      <i>",
"       J Hepatol",
"      </i>",
"      , 1995, 23(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/8530800/pubmed\" id=\"8530800\" target=\"_blank\">",
"        8530800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/50/36649/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8559 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36649=[""].join("\n");
var outline_f35_50_36649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708920\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182656\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182657\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182708\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182661\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182683\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182662\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2532858\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14211453\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182629\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874619\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182633\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182715\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182632\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7688405\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182717\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182706\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182636\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182617\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182702\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182652\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182625\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7688406\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182667\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7688408\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182639\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182638\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182627\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182640\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182635\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8559|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/34/550?source=related_link\">",
"      Indomethacin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=related_link\">",
"      Indomethacin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_50_36650="Neurofibromatosis type 1 (von Recklinghausen's disease)";
var content_f35_50_36650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurofibromatosis type 1 (von Recklinghausen's disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Sharon E Plon, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/50/36650/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/50/36650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis, or NF, is the term given to two distinct neurocutaneous genetic conditions. Neurofibromatosis type 1, also known as von Recklinghausen's NF or NF1 is the most common type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NF1 is an autosomal dominant genetic disorder with an incidence of approximately 1 in 2600 to 1 in 3000 individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately one-half of the cases are familial; the remainder are new mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. For reasons that are not well understood, the de novo mutations occur primarily in paternally derived chromosomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penetrance, or the likelihood that the individual carrying the mutation will be affected, is complete. However, NF1 is highly variable in its expression (ie, the severity of disease varies among affected individuals within the same family and from one family to another) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of NF1 does not differ between inherited and new mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NF1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     NF1",
"    </em>",
"    gene has been mapped to chromosome 17q11.2 and cloned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The gene is large, spanning over 350 kb of genomic DNA, and contains 60 exons. Neurofibromin, the protein product encoded by the gene, encompasses 2818 amino acids and has an estimated molecular mass of 327 kDa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/8\">",
"     8",
"    </a>",
"    ]. Neurofibromin is expressed in many tissues, including brain, kidney, spleen, and thymus.",
"   </p>",
"   <p>",
"    Mutations in the",
"    <em>",
"     NF1",
"    </em>",
"    gene result in loss of functional protein, causing the wide spectrum of clinical findings including NF1-associated tumors. Many mutations have been described and are cataloged in the International NF1 Genetic Analysis Consortium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/9\">",
"     9",
"    </a>",
"    ]. The types of mutations include cytogenetically visible translocations; intronic rearrangements affecting splicing, deletions, duplications, insertions; and many different point mutations and substitutions. Of the currently characterized mutations, approximately 82 percent are either nonsense or frameshift; they are likely to produce a truncated nonfunctional neurofibromin protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No obvious genotype-phenotype correlation between small mutations (&lt;20 base pairs) of the",
"    <em>",
"     NF1",
"    </em>",
"    gene and a specific phenotype have been demonstrated, with the exception of the c.2970-2972 delAAT (p.M990del) mutation that is associated with a very mild phenotype in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/10\">",
"     10",
"    </a>",
"    ]. The most striking finding is the paucity of cutaneous, subcutaneous, and superficial plexiform neurofibromas in these patients. The lack of neurofibromas may relate to the fact that unlike most other mutations that truncate or prevent neurofibromin formation, this mutation only deletes a single amino acid.",
"   </p>",
"   <p>",
"    About 1 to 5 percent of NF1 patients have large deletions that encompass more than 700 kb of DNA and include the entire",
"    <em>",
"     NF1",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ]. Such patients have a higher incidence of intellectual disability (mental retardation), some dysmorphic facial features, and earlier appearance of cutaneous neurofibromas. Data are conflicting as to whether individuals with large gene deletions also have an increased risk of malignant peripheral nerve sheath tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of tumor formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromin (Nf1) belongs to a family of GTPase-activating proteins (GAPs) that downregulate a cellular proto-oncogene, p21-ras, an important determinant of cell growth and regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Ras activates a number of signaling pathways that includes the stem cell factor",
"    <span class=\"nowrap\">",
"     (SCF)/c-kit",
"    </span>",
"    signaling, mTOR, and MAP kinase pathways.",
"    <em>",
"     NF1",
"    </em>",
"    plays a role as a tumor suppressor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an experimental mouse model, loss of both copies of the",
"    <em>",
"     NF1",
"    </em>",
"    gene in Schwann cells was sufficient to promote tumor formation, suggesting that tumor formation begins in these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/18\">",
"     18",
"    </a>",
"    ]. Although very small tumors formed when other cells in the mouse were wild-type for the",
"    <em>",
"     NF1",
"    </em>",
"    gene, tumor formation and infiltration of other cells (eg, mast cells and fibroblasts) resembling plexiform neurofibromas seen in patients were significantly enhanced by heterozygosity at the",
"    <em>",
"     NF1",
"    </em>",
"    locus in these non-tumorigenic cells. A subsequent study in this murine model showed that complete loss of",
"    <em>",
"     NF1",
"    </em>",
"    in Schwann cells and c-kit-dependent",
"    <em>",
"     NF1",
"    </em>",
"    haploinsufficiency in the bone marrow are necessary and sufficient for the initiation of tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Other studies suggest that this cellular infiltration is due to activation of pathways that may be inhibited by treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Peripheral neurofibromas'",
"    </a>",
"    below), which inhibits tyrosine kinases such as",
"    <span class=\"nowrap\">",
"     bcr/abl",
"    </span>",
"    and c-kit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of NF1 are the multiple caf&eacute;-au-lait spots (CALS) and associated cutaneous neurofibromas. The diagnostic criteria developed by the NIH Consensus Conference in 1987 and updated in 1997 are based upon specific clinical features of NF1 (",
"    <a class=\"graphic graphic_table graphicRef63696 \" href=\"mobipreview.htm?10/44/10955\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. According to these criteria,",
"    <strong>",
"     at least two",
"    </strong>",
"    of the following clinical features must be present to make the diagnosis of NF1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six or more caf&eacute;-au-lait macules &gt;5 mm in diameter in prepubertal and &gt;15 mm in diameter in postpubertal individuals; for each lesion, the longest diameter is measured.",
"     </li>",
"     <li>",
"      Two or more neurofibromas of any type or one plexiform neurofibroma (",
"      <a class=\"graphic graphic_picture graphicRef55032 \" href=\"mobipreview.htm?19/9/19601\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Freckling in the axillary or inguinal regions.",
"     </li>",
"     <li>",
"      Optic glioma.",
"     </li>",
"     <li>",
"      Two or more Lisch nodules (iris hamartomas).",
"     </li>",
"     <li>",
"      A distinctive bony lesion such as sphenoid dysplasia or thinning of the long bone cortex with or without pseudoarthrosis.",
"     </li>",
"     <li>",
"      A first-degree relative (parent, sibling, or offspring) with NF1 based upon the above criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One exception is that individuals with other conditions, including Legius syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/25,26\">",
"     25,26",
"    </a>",
"    ] and mismatch repair deficiency syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/27\">",
"     27",
"    </a>",
"    ], may manifest both caf&eacute;-au-lait spots and axillary freckling. Thus, there is increasing use of genetic testing in the diagnosis of NF1 for patients who meet only these two criteria. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The typical order of appearance of clinical features is caf&eacute;-au-lait spots, axillary freckling, Lisch nodules, and neurofibromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22\">",
"     22",
"    </a>",
"    ]. Osseous lesions, if present, usually appear during the patient's first year after birth, and symptomatic optic pathway glioma usually occurs by the time the patient is three years of age (",
"    <a class=\"graphic graphic_table graphicRef53064 \" href=\"mobipreview.htm?38/33/39451\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The NIH criteria are both highly specific and sensitive in all but the youngest children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22,28\">",
"     22,28",
"    </a>",
"    ]. In a study of 1893 NF1 patients younger than 21 years of age, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All met the criteria by 20 years of age.",
"     </li>",
"     <li>",
"      95 percent met them by eight years.",
"     </li>",
"     <li>",
"      Among patients younger than one year old, 70 percent had two or more clinical features, while 30 percent had only one feature. In the latter group, the patient must have an affected first-degree relative to meet the NIH criteria.",
"     </li>",
"     <li>",
"      Approximately 46 percent of sporadic NF1 patients failed to meet the NIH criteria by one year of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients have a condition known as segmental NF1, in which the clinical features of the disease occur in a limited anatomic area. Although they may meet the diagnostic criteria for NF1, the clinical course and mode of inheritance differ from the generalized condition. (See",
"    <a class=\"local\" href=\"#H49\">",
"     'Segmental NF1'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Caf&eacute;-au-lait spots",
"    </span>",
"    &nbsp;&mdash;&nbsp;CALS are flat, uniformly hyperpigmented macules, which appear during the first year after birth and usually increase in number during early childhood (",
"    <a class=\"graphic graphic_picture graphicRef69606 \" href=\"mobipreview.htm?11/56/12163\">",
"     picture 2",
"    </a>",
"    ). The number of CALS then stabilizes over time. As many as 25 percent of the normal population will have one to three CALS. However, the presence of six or more CALS is highly suggestive of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=see_link&amp;anchor=H8#H8\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Caf&eacute;-au-lait macule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a child with a negative family history and no other diagnostic features, CALS alone are insufficient to make a diagnosis of NF1. These children should be followed clinically for the appearance of other manifestations, as a definitive diagnosis usually can be made by the time the child is four years of age. Alternatively, genetic testing can be considered to make a molecular diagnosis (see",
"    <a class=\"local\" href=\"#H43\">",
"     'Genetic testing'",
"    </a>",
"    below). In one report of 41 children one month to 14 years of age with six or more CALS on the initial visit, a diagnosis of NF1 eventually was made in approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 95 percent of adults with NF1 have CALS, but they tend to fade later in life and may be difficult to distinguish in elderly individuals, particularly in African-Americans. A Wood's lamp often is useful to visualize these macules when they are not readily discernible by gross inspection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Legius syndrome, an autosomal dominant NF1-like disorder, results from germline loss-of-function mutations in SPRED1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. SPRED1 is a member of the",
"    <span class=\"nowrap\">",
"     SPROUTY/SPRED",
"    </span>",
"    family of proteins that act as negative regulators of RAS-RAF interaction and mitogen-activated protein kinase (MAPK) signaling. The clinical features include a subset of those of NF1 (multiple caf&eacute;-au-lait spots, axillary freckling, and macrocephaly) but importantly lack neurofibromas and central nervous system tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. Melanocytes from a CAL demonstrated both the germline SPRED1 mutation and an acquired somatic mutation in the wild-type SPRED1 allele, suggesting that complete SPRED1 inactivation is needed to generate a caf&eacute;-au-lait spot in this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Freckling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Freckling is a diagnostic criterion distinct from CALS. It occurs mostly in regions of skin apposition, especially the axillary and groin areas. Freckling usually is not apparent at birth but often appears by age four to five years. The occurrence of freckling in other intertriginous areas, such as the neckline or inframammary areas in women, suggests that these cutaneous lesions may be modulated by the local environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peripheral neurofibromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromas are benign tumors that are comprised of a mixture of Schwann cells, fibroblasts, and mast cells. The Schwann cells may be abnormal in NF1 patients. In plexiform neurofibromas (",
"    <a class=\"graphic graphic_picture graphicRef55032 \" href=\"mobipreview.htm?19/9/19601\">",
"     picture 1",
"    </a>",
"    ), they can have angiogenic and invasive properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Soft tissue sarcomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The four types of neurofibromas are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous",
"     </li>",
"     <li>",
"      Subcutaneous",
"     </li>",
"     <li>",
"      Nodular plexiform",
"     </li>",
"     <li>",
"      Diffuse plexiform",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous neurofibromas, the most common type, consist of soft fleshy tumors arising from cells in the peripheral nerve sheath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/33\">",
"     33",
"    </a>",
"    ]. In general, these dermal lesions begin to appear just before or during adolescence. They tend to increase in size and number with age. They vary in number from just a few to several hundred, with the highest density occurring over the trunk.",
"   </p>",
"   <p>",
"    Cutaneous neurofibromas are benign and do not carry an increased risk of developing malignant transformation. However, they often represent a major cosmetic problem in adults (",
"    <a class=\"graphic graphic_picture graphicRef82613 \" href=\"mobipreview.htm?31/6/31845\">",
"     picture 3",
"    </a>",
"    ). Pruritus associated with accelerated growth of neurofibromas may be a prominent and distressing symptom.",
"   </p>",
"   <p>",
"    Pregnancy can affect the number and size of neurofibromas, suggesting that these tumors have a hormone-responsive component. In a report of 247 pregnancies in 105 women, growth of new lesions and enlargement of existing lesions was reported in 60 and 55 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Subcutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous neurofibromas usually become apparent at the start of adolescence or early adulthood. These lesions present as firm, tender nodules along the course of peripheral nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Nodular plexiform",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular plexiform neurofibromas appear as complex clusters along proximal nerve roots and major nerves. They are similar to subcutaneous neurofibromas. These lesions can be a significant challenge in surgical treatment and pain management, especially with progressive growth along the spinal column that can cause vertebral erosion and may result in compression of the spinal cord. There are limited studies on use of medical therapies. In one case report, a large nodular plexiform decreased in size after the patient was treated with high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for a testicular seminoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/35\">",
"     35",
"    </a>",
"    ]. However, concerns remain regarding the toxicity of chemotherapeutic agents and the higher risk of secondary malignancy in patients with NF1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link\">",
"     \"Evaluation and management of pain in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diffuse plexiform",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although they often are not apparent in infants, diffuse plexiform neurofibromas are thought to be congenital lesions. In infants, hyperpigmentation of the skin may overlie an area where a lesion will develop and enlarge steadily with age.",
"   </p>",
"   <p>",
"    Plexiform neurofibromas (PN) represent a major cause of morbidity and disfigurement in individuals with NF1, and symptomatic PN are associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/36\">",
"     36",
"    </a>",
"    ]. These lesions usually involve multiple nerve fascicles, with serpiginous growth and significant vascularity, rendering complete surgical resection extremely difficult, if not impossible, to accomplish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/37\">",
"     37",
"    </a>",
"    ]. The management of these complex lesions is unclear, but the authors demonstrated that patients were more likely to benefit from surgery when the indications were airway compression or disfigurement. A smaller study with retrospective review of data from seven NF1 patients with massive PN indicated that the most common feature was that of a painful, expanding lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/38\">",
"     38",
"    </a>",
"    ]. A large prospective study of the natural history of plexiform neurofibromas was performed, but the data has not yet been reported.",
"   </p>",
"   <p>",
"    Surgical resection often is limited to debulking of a specific area of a large lesion, for example, when a component is impinging on the spinal cord or airway. Plexiform neurofibromas also can undergo malignant transformation to malignant peripheral nerve sheath tumors. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Soft tissue sarcomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    No specific treatment for neurofibromas exists. However, farnesyl transferase inhibitors, which inhibit the growth of these tumors in animals, are being tested in clinical trials of NF1 patients with enlarging plexiform neurofibromas. Phase I trials have been completed, showing that oral tipifarnib is well tolerated in children with refractory solid tumors and NF1-related plexiform neurofibromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/39\">",
"     39",
"    </a>",
"    ]. Further studies on the efficacy of this therapeutic intervention are ongoing; outcomes of phase II clinical trials are not yet published.",
"   </p>",
"   <p>",
"    Subsequent to the work on farnesyl transferase inhibitors, molecular work in recombinant mouse models demonstrated that the development of large plexiform neurofibromas required infiltration of the Schwann cells by activated mast cells dependent upon the c-kit receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/20\">",
"     20",
"    </a>",
"    ]. This work resulted in a phase 2 clinical trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (which targets the c-kit receptor) in children and adults with plexiform neurofibromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/21\">",
"     21",
"    </a>",
"    ]. The results of this trial showed that approximately 20 to 25 percent of patients showed some response to imatinib. Several other trials are underway to test a variety of agents for plexiform neurofibromas, including pegylated interferon-alpha-2b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/40\">",
"     40",
"    </a>",
"    ], and antiangiogenic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lisch nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lisch nodules characteristically are raised, often pigmented hamartomas of the iris and represent a relatively specific finding for NF1. These do not affect vision in any manner.",
"   </p>",
"   <p>",
"    Lisch nodules are useful both in establishing a diagnosis of NF1 in a child and determining whether a parent is affected. These lesions are detected in fewer than 10 percent of affected children younger than six years of age but are seen in greater than 90 percent of adults. They may be seen with a direct ophthalmoscope if the nodules are large or numerous and the iris is light (",
"    <a class=\"graphic graphic_picture graphicRef74414 \" href=\"mobipreview.htm?2/49/2837\">",
"     picture 4",
"    </a>",
"    ). However, we recommend a thorough slit-lamp examination by an ophthalmologist to detect the lesions and to distinguish them from iris nevi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bony abnormalities in NF1 include pseudoarthrosis and bone dysplasia, which are part of the NIH Consensus Conference criteria for the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], as well as short stature, scoliosis, and osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pseudoarthrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pseudoarthrosis, or false joint, is formed because of nonunion of bone fragments. Pseudoarthrosis in NF1 results from impaired healing because of bone dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long bone pseudoarthrosis is a characteristic skeletal lesion that occurs in infancy in approximately 5 percent of patients with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/44\">",
"     44",
"    </a>",
"    ]. Similar to other lesions in NF1, analysis of the bone at the site of pseudoarthrosis reveals loss of heterozygosity at the NF1 locus consistent with a second mutation event that leads to complete inactivation of the NF1 gene in these tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/45\">",
"     45",
"    </a>",
"    ]. NF1 is the most common cause of long bone pseudoarthrosis, accounting for 50 to 80 percent of cases. Thus, evaluation for NF1 should be performed in a child with this condition.",
"   </p>",
"   <p>",
"    Pseudoarthrosis typically presents in infants or young children as bowing of the tibia, which progresses to thinning of the cortex and fracture. It has a male predominance (1.7:1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/44\">",
"     44",
"    </a>",
"    ]. The diagnosis may be overlooked until pathologic fractures occur with weight bearing or when walking is first attempted in toddlers. Approximately one-half of fractures occur before the patient is two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudoarthrosis severely compromises function in the affected limb. In some cases, mobility may be improved by amputation of the foot and replacement with a prosthesis. In a report of 75 patients with NF1 and pseudoarthrosis, 16 percent had an amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal involvement can include numerous other lesions that are characteristic clinical features of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/24\">",
"     24",
"    </a>",
"    ]. They include vertebral defects, such as scalloping caused by dural ectasia, cortical thinning of the long bones, and sphenoid wing dysplasia, which may present as facial asymmetry. Young children with NF1 may have a hair whorl overlying an area of vertebral dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/46\">",
"     46",
"    </a>",
"    ]. The primary pathologic mechanism for the bone dysplasia is uncertain, because most clinical features of NF1 are caused by involvement of neural crest cells, although RAS signaling is active in osteoblasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NF1 frequently have short stature. In a database of 569 white North American patients with NF1, 13 percent had a height &ge;2 standard deviations below the population mean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47\">",
"     47",
"    </a>",
"    ]. Growth curves for children with NF1 are available and can aid the clinician in determining if short stature is consistent with the diagnosis of NF1 or is more severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]; the latter suggests an additional cause and requires evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis occurs in 10 to 25 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. This condition frequently becomes apparent at 6 to 10 years of age or in early adolescence. The most common type of scoliosis is kyphosis, the anterior angulation involving the cervical and upper thoracic spine. Orthopedic intervention, such as bracing or surgery, may be needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23\">",
"     23",
"    </a>",
"    ]. The requirement for surgical management of dystrophic scoliosis may further complicate the clinical picture of chronic pain management for individuals with NF1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link\">",
"     \"Evaluation and management of pain in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with NF1 have lower bone density per age compared with general population controls. Characterization of 74 NF1 patients (children and young adults) by DXA scans found statistically significant and generalized reduction in bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/42\">",
"     42",
"    </a>",
"    ]. The severity of decreased bone density can range from osteopenia to osteoporosis. The etiology of this decrease in bone density is unknown. Treatment with calcium and vitamin D alone did not appear to increase bone density in a small trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/42\">",
"     42",
"    </a>",
"    ]. Further studies are needed to determine whether early intervention with bisphosphonates is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NF1 develop both benign and malignant tumors at increased frequency throughout life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/37,49\">",
"     37,49",
"    </a>",
"    ]. Optic pathway gliomas are the predominant type of intracranial neoplasms, but other central nervous system (CNS) and non-CNS tumors can occur.",
"   </p>",
"   <p>",
"    The overall risk of malignancy in NF1 is estimated at between 5 and 15 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. This rate is approximately 2.5 to fourfold higher than that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CNS neoplasms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Optic pathway gliomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic pathway gliomas (OPGs) occur in 15 percent of children younger than six years of age with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/53\">",
"     53",
"    </a>",
"    ]; they may rarely occur in older children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. With magnetic resonance imaging (MRI), they appear as an enlargement of the optic nerve or chiasm. These tumors, which are typically low-grade gliomas, may arise anywhere along the anterior visual pathway to the optic radiations and involve the optic nerves, chiasm, and post-chiasmal optic tracts. These tumors appear to have a more benign course in patients with NF1 than in those without NF1, but there may be a degree of ascertainment bias since patients with NF1 may be screened for optic pathway gliomas, whereas sporadic cases are only identified when they are symptomatic or a brain scan is undertaken for other reasons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/16/39176?source=see_link\">",
"     \"Optic pathway glioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presentation &mdash; Many children with NF1 and OPGs have normal vision. However, a minority of children become symptomatic with progressive vision loss associated with an expanding lesion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,53,56,57\">",
"       2,53,56,57",
"      </a>",
"      ]. Symptoms and signs of OPG may include decreased visual acuity or color vision, abnormal pupillary function, proptosis, and optic nerve atrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/58-60\">",
"       58-60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Children with advanced tumors involving the optic chiasm occasionally present with either premature or delayed puberty caused by hypothalamic involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/57\">",
"       57",
"      </a>",
"      ]. Detecting precocious puberty early in patients with NF1 is important because it may indicate the presence of an optic pathway glioma. In addition, treatment can minimize the complications of accelerated linear bone growth and premature development of secondary sexual characteristics. One of the earliest signs of precocious puberty is accelerated linear growth, which highlights the importance of maintaining accurate growth charts using standards for children with NF1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47,48,61,62\">",
"       47,48,61,62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link\">",
"       \"Definition, etiology, and evaluation of precocious puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening &mdash; Because of the variable natural history of these tumors, all children with NF1 should undergo thorough ophthalmologic evaluation and regular growth assessments using standard growth charts for children with NF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47,48,61,62\">",
"       47,48,61,62",
"      </a>",
"      ]. Ideally, ophthalmologic screening should include visual acuity testing, confrontation visual field testing, color vision testing, and assessment of pupils, eyelids, extraocular motility, and irises, and fundi, although the full range of assessment may not be feasible in the infant or young child. The evaluation should begin when NF1 first is suspected and be repeated at annual intervals or when symptoms develop.",
"      <br/>",
"      <br/>",
"      Any child with visual symptoms or physical signs (eg, proptosis, decreased visual acuity, or precocious puberty) should have an MRI to investigate for an OPG. A consensus panel convened by the Children's Tumor Foundation (previously called the National Neurofibromatosis Foundation) did not recommend neuroimaging for screening in asymptomatic children with NF1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/61\">",
"       61",
"      </a>",
"      ] and many NF clinics follow young children with NF1 according to these guidelines.",
"      <br/>",
"      <br/>",
"      However, at Texas Children's Hospital, we perform systematic surveillance with MRI of the brain and orbits at one to two and two to three years of age to detect optic pathway tumors before they become symptomatic primarily because of the difficulty assessing vision in this age group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/46\">",
"       46",
"      </a>",
"      ]. After the age of three, the ophthalmic examination alone is performed and an MRI is only recommended if that is abnormal. If a child is first diagnosed after the age of three and before the age of six, we recommend a single screening MRI. If the MRI is positive for OPG, MRI and ophthalmic examination are repeated every three to six months; if the optic pathway tumor progresses, the child is referred to Neurooncology for evaluation.",
"      <br/>",
"      <br/>",
"      The outcome of systematic screening for OPG with MRI and ophthalmic examinations in young children was evaluated in a clinical study of children (&lt;6 years of age) at Texas Children's Hospital [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/63\">",
"       63",
"      </a>",
"      ]. OPG were detected in 9 of 69 children who were asymptomatic and had normal ophthalmic examinations. Three of these children were treated with chemotherapy (due to progression of the lesion on subsequent MRI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ophthalmic examination) and retained normal visual function.",
"      <br/>",
"      <br/>",
"      These observations suggest that systematic screening for OPG permits early intervention and may reduce complications. However, this was not a randomized study and other experts in the field disagree with the use of MRI for screening, as described in the commentary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/64\">",
"       64",
"      </a>",
"      ] that accompanied the publication of the Texas Children' Hospital study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/63\">",
"       63",
"      </a>",
"      ] and the 2007 Children's Tumor Foundation consensus panel statement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/61\">",
"       61",
"      </a>",
"      ]. However, there is a consensus that it is important to make the clinical diagnosis of NF1 in very young children so that ophthalmic evaluations are initiated. As an example, in the Texas Children's Hospital study, four of six children who presented with proptosis or visual impairment had not had a prior diagnosis of NF1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Follow-up &mdash; There is little consensus regarding the frequency of visual examinations and neuroimaging for children with NF1 in whom OPG have been identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/61\">",
"       61",
"      </a>",
"      ]. The suggested intervals vary between 3 and 24 months depending upon the tumor site, severity of visual impairment, and the evidence of progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/60,65-67\">",
"       60,65-67",
"      </a>",
"      ]. The treatment of OPGs is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/16/39176?source=see_link&amp;anchor=H12#H12\">",
"       \"Optic pathway glioma\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other CNS neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to OPGs, individuals with NF1 are at increased risk for developing other CNS neoplasms, particularly astrocytomas and brainstem gliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/57,68,69\">",
"     57,68,69",
"    </a>",
"    ]. Although astrocytomas usually arise in early childhood (mean age at diagnosis 4.5 years), the risk persists into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/54\">",
"     54",
"    </a>",
"    ]. The most frequent clinical presentation is that of increased intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with NF1 who develop optic pathway tumors are at a particularly high risk for a second CNS neoplasm. In one report of 154 NF1 patients with OPG, 11 percent had a second CNS tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the risk of non-CNS tumors was not increased by the presence of an optic pathway tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Prognosis of CNS tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of CNS tumors in individuals with NF1 is not well documented. One retrospective French study included 88 children (3 months to 17 years old) and 16 adults (19 to 52 years old) with NF1 who developed CNS tumors over a period between 1982 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/57\">",
"     57",
"    </a>",
"    ]. Of the 127 CNS tumors that developed in these 104 subjects, OPGs and extra-optic pathway tumors accounted for 66 and 34 percent, respectively. One-half of the extra-optic pathway gliomas presented in the brainstem.",
"   </p>",
"   <p>",
"    Treatment was undertaken in the minority of patients with both OPG and extra-optic pathway tumors (8 of 84, and 23 of 53 patients, respectively). Despite this, the five-and ten-year survival rates were 90 and 82 percent when all patients were considered. Factors associated with significantly shorter survival were extra-optic location, and tumor diagnosis in adulthood; there was a trend toward shorter survival in symptomatic compared to asymptomatic patients. Growth hormone deficiency (46 percent) and ischemic stroke (32 percent) were frequent complications of radiotherapy in patients with OPG. Minimization of radiation treatment is a goal when planning treatment of patients with NF1 and CNS tumors, because of concerns about second malignancies and vascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Soft tissue sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plexiform neurofibromas can undergo malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs), which were previously referred to as neurofibrosarcomas. Among children with MPNSTs, 20 to 50 percent have had NF1 in reported series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifetime risk of developing an MPNST in patients with NF1 has varied among studies with estimates ranging from 5 to 13 percent depending on the series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/72,74-76\">",
"     72,74-76",
"    </a>",
"    ]. MPNST usually, but not invariably, arises within preexisting plexiform neurofibromas.",
"   </p>",
"   <p>",
"    MPNST is an aggressive and potentially fatal malignancy. In one series of 36 patients with MPNST arising in the setting of NF1, the five-year event-free and overall survival rates were only 19 and 28 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/77\">",
"     77",
"    </a>",
"    ]. In another series, five-year survival was decreased in patients with NF1-associated MPNST compared with sporadic MPNST (33 versus 63 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/78\">",
"     78",
"    </a>",
"    ]. Patients with NF1 tend to have larger tumors at diagnosis, underscoring the importance of early detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some authors suggest the possibility of screening by MRI for MPNST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/78\">",
"     78",
"    </a>",
"    ], such screening is not incorporated into NF1 guidelines given the long period of risk (adolescence through mid-adulthood) and the variable location of tumor development. However, the first presentation of malignant transformation often is significant chronic pain, change in consistency, or rapid growth of a nodule within an existing plexiform neurofibroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/11,73\">",
"     11,73",
"    </a>",
"    ]. Primary care clinicians, parents, and children entering adolescence should be educated about this possibility and strongly encouraged to report the development of any signs or symptoms to a clinician familiar with NF1. Prompt investigation, including MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/80\">",
"     80",
"    </a>",
"    ], should be initiated.",
"   </p>",
"   <p>",
"    Some experts also consider the addition of positron emission tomographic (PET) scanning to aid in the distinction between an MPNST and a benign plexiform neurofibroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/73,81-83\">",
"     73,81-83",
"    </a>",
"    ]. Biopsy of several sites within a preexisting plexiform neurofibroma may be indicated to determine if malignant transformation has occurred. MPNST also occur in patients with NF1 who do not have a prior plexiform neurofibroma. Given the poor prognosis for this entity, there are open clinical trials using new combinations of chemotherapy through the Children's Oncology Group in both sporadic and NF1-associated, high-grade, unresectable MPNST.",
"   </p>",
"   <p>",
"    Among nonneurogenic sarcomas, rhabdomyosarcoma (RMS) is encountered more frequently in NF1 patients than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/77,84,85\">",
"     77,84,85",
"    </a>",
"    ]. Cases tend to present at an early age, and they often arise in a genitourinary site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/77\">",
"     77",
"    </a>",
"    ]. Treatment outcomes appear similar to those in the general RMS population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients are also at increased risk of developing soft tissue sarcomas that arise within the stromal compartment of the gastrointestinal tract, termed gastrointestinal stromal tumors (GISTs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. In the setting of NF1, they are frequently in the small intestine (more than 70 percent), often multiple, and have a different molecular pathology. Although pheochromocytomas are a rare finding in patients with NF1, there was a frequent co-occurrence of GIST tumors and pheochromocytoma in one series, suggesting any patient undergoing surgical procedures for a GIST tumor should be first screened for the presence of a pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/89\">",
"     89",
"    </a>",
"    ]. Unlike GISTs that arise outside of the setting of NF1, only a few cases have been reported to carry somatic mutations in the KIT or PDGFRA genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/86,90\">",
"     86,90",
"    </a>",
"    ]. Consistent with this finding, the tumors have been poorly responsive to the tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link&amp;anchor=H1013925#H1013925\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Pediatric GIST'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Molecular pathogenesis of GIST and KIT mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H9#H9\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Influence of mutations on response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether other common malignancies occur at higher rates in patients with NF1 is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/52,91\">",
"     52,91",
"    </a>",
"    ]. In some reports, NF1 patients have an increased risk of certain other malignancies, including chronic myeloid leukemias of childhood, and pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/92\">",
"     92",
"    </a>",
"    ]. However, large studies of patients with pheochromocytoma demonstrate that genetic etiologies other than NF1 (eg, multiple endocrine neoplasia type 2, von Hippel Lindau syndrome) are much more common causes.",
"   </p>",
"   <p>",
"    One follow-up study consisted of 174 adults, averaging 16 years after their original diagnosis (between 1978 and 1984) with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/50\">",
"     50",
"    </a>",
"    ]. It found that the risk of malignancy was increased compared to a control population and was substantially higher in women than in men with NF1. The risk of common cancers (eg, breast, colon, prostate) was not increased in this cohort. Another study of 304 women with NF1 from the United Kingdom found a moderately increased risk of developing breast cancer compared with the general population and suggested that early screening (ie, mammography at age &ge;40 years) be considered for women with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/93\">",
"     93",
"    </a>",
"    ]. In two retrospective series, the incidence of breast cancer was higher in women with NF1, particularly those under 50 years of age, compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     NEUROLOGIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic disorders include cognitive deficits, learning disabilities, seizures, and neuroimaging abnormalities. Macrocephaly is a common feature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cognitive deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive deficits and learning disabilities occur with higher frequency in children with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/96\">",
"     96",
"    </a>",
"    ]. IQ scores are 5 to 10 points lower in children with NF1 compared to the general population or unaffected sibling controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/97\">",
"     97",
"    </a>",
"    ]. A study of 81 children with NF1 found moderate to severe impairment involving one or more domains of cognitive function in 66 (81 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/98\">",
"     98",
"    </a>",
"    ]. One-half of the children performed poorly on tasks of reading, spelling, and mathematics, but only 20 percent had specific learning disabilities (defined by discrepancy in IQ and achievement). In another study of 66 children with NF1, the most common developmental abnormalities found were gross motor (52 percent), fine motor (35 percent), and",
"    <span class=\"nowrap\">",
"     premath/math",
"    </span>",
"    (31 percent) delays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cognitive deficits and learning disabilities are common in children with NF1, the incidence of intellectual disability (full scale IQ &lt;70) in this disorder is 4 to 8 percent, only slightly higher than that of the general population (2 to 3 percent). Thus, a child with NF1 and intellectual disability should be evaluated for other causes of cognitive impairment (eg, fragile X syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intellectual impairment appears to be unrelated to gender, socioeconomic class, disease severity, or family history of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/96\">",
"     96",
"    </a>",
"    ]. Cognitive deficits and learning disabilities occur in children with and without lesions detected on MRI.",
"   </p>",
"   <p>",
"    A preclinical trial using a mouse model of NF1 which demonstrates learning deficits",
"    <span class=\"nowrap\">",
"     (nf1+/-)",
"    </span>",
"    revealed that increased",
"    <span class=\"nowrap\">",
"     RAS/ERK",
"    </span>",
"    signaling is the mechanism underlying the deficits in neuronal plasticity as well as the spatial and attention deficits of these mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/100\">",
"     100",
"    </a>",
"    ]. Treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    (a statin that transverses the blood-brain barrier), reversed these deficits on a number of tests in",
"    <span class=\"nowrap\">",
"     nf1+/-",
"    </span>",
"    adult mice, but had little to no impact on wild-type littermates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first randomized controlled trial of statins in humans,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (a related drug) did not improve cognitive function in 62 children (aged 8 to 16 years) with NF1; however the children were not selected for preexisting learning disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/101\">",
"     101",
"    </a>",
"    ]. A phase I study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    in 24 children with NF1 and a documented history of learning disabilities demonstrated improvements in verbal and nonverbal memory and visual attention and efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/102\">",
"     102",
"    </a>",
"    ]. Only minimal side effects were noted. Several other clinical trials of statins to determine if they improve cognitive functioning in patients with NF1 are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Specific learning disabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific learning disability, defined as a significant discrepancy between ability and academic achievement, occurs in 20 to 65 percent of patients with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. Affected children demonstrate a range of neuropsychologic impairments, including poor performance on non-verbal learning problems (ie, difficulty with written work, poor attention, and decreased organizational skills), tests of visuospatial function, and language-based learning tasks (ie, reading and spelling) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/97\">",
"     97",
"    </a>",
"    ]. Attention deficit-hyperactivity disorder occurs in 38 to 39 percent of children with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/98,103\">",
"     98,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H13#H13\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Problems with articulation (speech) also occur commonly. Cognitive deficits, combined with the physical manifestations of the disorder, may have a negative impact on self-esteem in school age children with NF1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link&amp;anchor=H8#H8\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur a little more often in patients with NF1, although they are not a frequent complication. In a series of 499 affected patients, the prevalence of seizures was 4.2 percent, approximately twice that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/104\">",
"     104",
"    </a>",
"    ]. Seizures can be of any type and begin at any age; given the increased risk for CNS tumors in NF1, an MRI of the brain should be performed at the first diagnosis of seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Macrocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head size is generally larger in children with NF1 and absolute macrocephaly occurs in 25 to 50 percent of children with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47,105\">",
"     47,105",
"    </a>",
"    ]. It is caused by increased brain volume due to inherent skeletal features of the disorder and may be associated with cognitive problems. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Increased brain volume (megalencephaly)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An infant with acute acceleration in head growth should be evaluated for hydrocephalus due to aqueductal stenosis and CNS neoplasms. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Other CNS neoplasms'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is much less common in NF1 than in NF2, with reports of nerve compression in up to 4 percent of patients and spinal root compression in up to 3 percent in patients with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,28,68,106\">",
"     2,28,68,106",
"    </a>",
"    ]. By comparison clinical symptoms of peripheral neuropathy occur in almost 50 percent of patients with NF2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=see_link\">",
"     \"Neurofibromatosis type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, peripheral neuropathy can be a severe complication of NF1 that is associated with frequent morbidity related to spinal complications and development of malignant peripheral nerve sheath tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/107\">",
"     107",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Soft tissue sarcomas'",
"    </a>",
"    above). The natural history of pain due to spinal lesions in individuals with NF1 should be taken into consideration in deciding management of such tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link\">",
"     \"Evaluation and management of pain in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Neuroimaging abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities frequently are detected by performing neuroimaging in patients with NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/108\">",
"     108",
"    </a>",
"    ]. These include NF-associated bright spots and increased brain volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     NF-associated bright spots or vacuolation changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal areas of increased signal intensity were first identified on T2 weighted MRIs of the brain in children with NF1 and are sometimes, referred to as unidentified bright objects (UBOs), a term that can be upsetting to parents; they also may be called vacuolation changes or dysplastic changes. They are a characteristic finding in 60 to 70 percent of NF1 patients. These bright spots occur most often in the basal ganglia, cerebellum, brainstem, and subcortical white matter and are thought to represent increased fluid within the myelin associated with dysplastic glial proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. They do not behave in a malignant or premalignant manner. In general, these lesions are not associated with focal neurologic deficits, and they tend to disappear with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Their clinical significance is unknown.",
"   </p>",
"   <p>",
"    Data are conflicting on the relationship between NF-associated bright spots and cognitive function. In one report, 25 of 40 children (62 percent) with NF1 had bright spots present on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/112\">",
"     112",
"    </a>",
"    ]. These patients had significantly lower IQ and language scores and impaired visuomotor integration and coordination, compared to children without them. In another study, the number of locations containing spots accounted for much of the lowering of IQ scores in NF1 patients compared to unaffected siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/113\">",
"     113",
"    </a>",
"    ]. However, in a third series, these lesions were not associated with intellectual impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Increased brain volume (megalencephaly)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain volumes are increased in patients with NF1 and may be related to cognitive abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/105,108,114,115\">",
"     105,108,114,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Cerebrovascular dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective series have noted abnormal cerebral vasculature (eg, moyamoya syndrome, intracranial aneurysm) in 2 to 6 percent of children with NF1 who underwent neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. Most patients were asymptomatic despite angiographic progression, but some required surgery for revascularization. The presence of cerebrovascular dysplasia needs to be taken into account if neurosurgery or radiation therapy is being considered for a patient with NF1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NF1 should be monitored for developmental progress. A careful neurologic examination should be part of the evaluation performed at yearly intervals. A developmental history should be obtained and school progress reviewed. If areas of concern are identified, a formal educational assessment should be performed promptly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Academic support should be available for children with learning disabilities. Speech, occupational, and physical therapy should be provided for children with speech problems and motor impairment involving balance and gait. Some children have attention deficit disorder, with or without hyperactivity, which may respond to stimulant medication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898700#H2007898700\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Stimulants versus other medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H2#H2\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Core symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link&amp;anchor=H830607547#H830607547\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the uncertain relationship between MRI findings and learning disabilities, neuroimaging should",
"    <strong>",
"     not",
"    </strong>",
"    be part of a routine diagnostic evaluation. However, MRI should be performed to evaluate specific neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a frequent finding in adults with NF1 and may develop during childhood. Hypertension is considered essential in most cases, but vascular lesions producing renovascular hypertension are more frequent in NF1 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,119\">",
"     2,119",
"    </a>",
"    ]. Renovascular lesions can be detected in patients who are still normotensive; the frequency with which such patients will develop hypertension is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/119\">",
"     119",
"    </a>",
"    ]. A much less common cause of hypertension in NF1 is pheochromocytoma, which has been clinically identified in 0.1 to 5.7 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=see_link\">",
"     \"Pheochromocytoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with NF1 or at risk for having the disorder must have regular blood pressure monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    periodic ambulatory blood pressure monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/120\">",
"     120",
"    </a>",
"    ]. Patients with severe hypertension should be evaluated for renal artery stenosis and if negative, then consider evaluation for pheochromocytoma. Correction of the underlying lesion typically lowers the blood pressure in these settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=see_link\">",
"     \"Ambulatory blood pressure monitoring in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=see_link\">",
"     \"Pheochromocytoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about the effect of NF1 on mortality is limited, although life expectancy appears to be shortened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/2,121,122\">",
"     2,121,122",
"    </a>",
"    ]. In one report using data from United States death certificates for 1983 through 1997, the age at death was reduced for NF1 patients (mean 54.5 versus 70.1 years, median 59 versus 74 years) compared to that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/121\">",
"     121",
"    </a>",
"    ]. NF1 patients were more likely to have a malignant neoplasm listed on their death certificates, especially if death occurred before they reached 30 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many cases of NF1 are new mutations, parents often are surprised and distressed when the diagnosis is made. In addition, even in familial cases, it is not unusual to make a diagnosis of NF1 in one of the parents after the diagnosis has first been made in their child.",
"   </p>",
"   <p>",
"    When the diagnosis is made in a child with no family history of the disorder, both parents should be thoroughly evaluated. This evaluation includes a complete examination of the skin and a slit lamp examination of the eyes because of the variable expressivity characteristic of this disorder.",
"   </p>",
"   <p>",
"    Because NF1 has an autosomal dominant inheritance pattern, the risk of having this disorder in each offspring of an affected parent is 50 percent. However, if neither parent meets the clinical criteria for NF1, the risk of the parents having another child with NF1 is less than 1 percent (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above). When this occurs, it is most often caused by germ-line mosaicism such that a proportion of the gonadal tissue contains the mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. However, the rate of germ-line mosaicism in NF1 is much lower than in NF2, osteogenesis imperfecta, and some other dominant disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular testing for mutations in",
"    <em>",
"     NF1",
"    </em>",
"    is clinically available. Mutations associated with the clinical diagnosis disrupt the function of the",
"    <em>",
"     NF1",
"    </em>",
"    gene. Because of the large size of the gene and the heterogeneity of mutations, molecular testing is complex, including sequencing of all of the coding exons as well as tests for deletions or rearrangements of a portion or the entire gene. This type of comprehensive molecular testing, which is clinically available, is reported to find the causative DNA mutation in approximately 95 percent of patients who carry the clinical diagnosis of NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/126\">",
"     126",
"    </a>",
"    ]. Thus, a negative test does not completely exclude the diagnosis.",
"   </p>",
"   <p>",
"    With the identification of mutations in",
"    <em>",
"     SPRED1",
"    </em>",
"    resulting in caf&eacute;-au-lait macules and axillary freckling, clinicians are now using genetic testing for patients (often young children) with only these diagnostic features to determine whether the child has NF1 or Legius syndrome. If the test is positive for an",
"    <em>",
"     NF1",
"    </em>",
"    mutation, the period of diagnostic uncertainty is shortened, and appropriate screening evaluations (eg, ophthalmic screens) are initiated promptly. If the",
"    <em>",
"     NF1",
"    </em>",
"    testing is negative, then the diagnostic laboratory will perform",
"    <em>",
"     SPRED1",
"    </em>",
"    mutation testing.",
"   </p>",
"   <p>",
"    However, it is important to emphasize that in the majority of cases a positive",
"    <em>",
"     NF1",
"    </em>",
"    mutation test does not necessarily predict the severity or complications of the disorder. Children with a deletion that includes the entire",
"    <em>",
"     NF1",
"    </em>",
"    gene have been reported to have significant developmental delay, some facial dysmorphism, earlier onset of cutaneous neurofibroma, and connective tissue abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. The parents of young children with multiple caf&eacute;-au-lait spots should understand the risks and benefits of genetic analysis before proceeding with testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Prenatal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of clinical mutation testing has also made prenatal testing for NF1 by amniocentesis or chorionic villus sampling technically feasible. Preimplantation genetic diagnosis (PGD) that involves beginning pregnancy through in vitro fertilization and biopsy of the blastocyst to identify those embryos which are unlikely to carry the NF1 mutation has been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/129\">",
"     129",
"    </a>",
"    ]. Both methods require that the specific",
"    <em>",
"     NF1",
"    </em>",
"    mutation be identified in the prospective parent before PGD or prenatal diagnosis is initiated.",
"   </p>",
"   <p>",
"    Prenatal genetic testing can also be performed using linkage analysis for familial cases of NF1 where a specific",
"    <em>",
"     NF1",
"    </em>",
"    mutation is not identified. Linkage analysis traces polymorphic markers near the",
"    <em>",
"     NF1",
"    </em>",
"    gene through the affected members of the family. Linkage analysis requires DNA samples from several affected family members so it is not available for an adult who is the first member of the family with NF1. A geneticist or genetic counselor must interpret the results.",
"   </p>",
"   <p>",
"    Reproductive decisions by couples are facilitated by appropriate genetic counseling about the availability of prenatal or preimplantation testing described above. Prospective parents should be aware that NF1 exhibits wide clinical variability within families and that establishing the diagnosis prenatally cannot predict the severity or outcome. The couple should also be informed that their risk of having an affected child can be substantially lowered by use of other reproductive technologies, including sperm or oocyte donation, depending upon which parent is affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26257?source=see_link\">",
"       \"Patient information: Neurofibromatosis type 1 (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children suspected of having NF1 should be evaluated by a multidisciplinary team that includes pediatric neurology, genetics, and ophthalmology. Referral to dermatology, neurosurgery, plastic surgery, and pediatric endocrinology may be indicated for some children. Both an expert panel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23\">",
"     23",
"    </a>",
"    ] and the Genetics Committee of the American Academy of Pediatrics have published diagnostic and health supervision guidelines for children with NF1 (",
"    <a class=\"external\" href=\"file://pediatrics.aappublications.org/cgi/reprint/121/3/633.pdf\">",
"     pediatrics.aappublications.org/cgi/reprint/121/3/633.pdf",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial screening evaluation should confirm the diagnosis by identifying clinical features of NF1. History should be obtained regarding symptoms associated with the disorder, such as pain, visual complaints, weakness or neurologic deficits, headaches, and seizures. The developmental history and school progress should be reviewed. A detailed family history also should be obtained to detect possible symptoms of NF1. When possible, parents and siblings should be examined for characteristic signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23\">",
"     23",
"    </a>",
"    ]. Genetic testing can be helpful in confirming the diagnosis for children who do not meet diagnostic criteria and for providing information to parents about risk to family members. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H43\">",
"     'Genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The multidisciplinary team should examine the child for diagnostic criteria and treatable complications, and also provide anticipatory guidance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination should focus on skin, skeletal, and neurologic systems.",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation should be performed to identify Lisch nodules and early signs of optic pathway glioma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical evaluation appears to be more useful to detect complications than are screening investigations in asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23,130\">",
"     23,130",
"    </a>",
"    ]. Thus, for example, guidelines of the Children's Tumor Foundation (formerly the National Neurofibromatosis Foundation) do not recommend neuroimaging as a screening modality for optic pathway gliomas, although not all authors agree. The decision to obtain screening studies depends upon the history and physical findings. Examples include MRI of the orbits and brain if eye or neurologic abnormalities are detected and radiographs of the skull, chest, and spine if bony abnormalities are found. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Optic pathway gliomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal care for individuals with NF1 aims at the early detection and symptomatic treatment of complications as they occur. In providing medical supervision to children with NF1, the frequency of follow-up visits should increase to address disease complications. Regular visits at yearly intervals should include (",
"    <a class=\"external\" href=\"file://pediatrics.aappublications.org/cgi/content/full/121/3/633\">",
"     file://pediatrics.aappublications.org/cgi/content/full/121/3/633",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Examine skin for new peripheral neurofibromas, signs of plexiform neurofibromas, or progression of existing lesions.",
"     </li>",
"     <li>",
"      Check blood pressure annually for signs of developing hypertension.",
"     </li>",
"     <li>",
"      Evaluate growth measurements including height, weight, and head circumference.",
"     </li>",
"     <li>",
"      Evaluate for skeletal changes, including scoliosis, vertebral changes, and limb abnormalities, particularly tibial dysplasia in young patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmologic examination &mdash; Obtain a formal ophthalmologic evaluation yearly, including visual screening.",
"     </li>",
"     <li>",
"      Assessment for precocious puberty &mdash; Evaluate older children for secondary sexual characteristics or abnormal growth acceleration that may be associated with lesions of the pituitary from optic glioma involving the chiasm.",
"     </li>",
"     <li>",
"      Developmental assessment &mdash; Evaluate neurodevelopmental progress and evidence for attention deficit disorder.",
"     </li>",
"     <li>",
"      Review of school progress &mdash; Recommend available resources for patients with NF1 and learning difficulties. IQ testing and neuropsychologic evaluation may identify cognitive deficits early and facilitate the use of academic support in school [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monitoring of plexiform neurofibromas &mdash; Patients should be questioned, particularly in adolescence, about any change in pain or growth pattern associated with a preexisting plexiform neurofibroma and, if found, should be evaluated for possible malignant transformation of the neurofibroma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any unexplained complications are identified, or if cutaneous or deep lesions appear to be growing rapidly, coordination of referral to the appropriate subspecialist for further evaluation and management is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling should be provided for patients and families. It should include information on the inheritance of the disorder, prognosis, and psychosocial adjustment. The progressive nature of the disease and its clinical manifestations and complications should be addressed. (See",
"    <a class=\"local\" href=\"#H42\">",
"     'Genetic counseling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The genetics of NF1, including potential recurrence risk in other offspring, should be explained to the parents of affected children. Specific counseling may be warranted for adolescents with NF1 who face issues with self-esteem and the psychosocial impact of this condition.",
"   </p>",
"   <p>",
"    The Childhood Tumor Foundation",
"    <span class=\"nowrap\">",
"     (www.ctf.org/)",
"    </span>",
"    provides information about the disorder and general support. Referral of the family to a local chapter often is helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SEGMENTAL NF1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental NF1 occurs when clinical features of the disease are limited to one area of the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. The most common manifestations are localized caf&eacute;-au-lait spots and neurofibromas. The incidence is estimated at one in 36,000 to 40,000 in the United Kingdom and Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental NF1 is caused by somatic mosaicism due to a postzygotic mutation in the",
"    <em>",
"     NF1",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/133\">",
"     133",
"    </a>",
"    ]. This results in some cells having two normal",
"    <em>",
"     NF1",
"    </em>",
"    genes and other cells containing a mutation in one copy of the",
"    <em>",
"     NF1",
"    </em>",
"    gene. In most cases, patients have no affected relatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of segmental and generalized NF1 is similar with regard to the age of appearance of the specific features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. Pigmentary features and plexiform neurofibromas tend to present in children, while neurofibromas develop in adults. Caf&eacute;-au-lait spots appear before freckling.",
"   </p>",
"   <p>",
"    In most patients, the affected area was limited to one side, with involvement ranging from a narrow strip to one-half of the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131\">",
"     131",
"    </a>",
"    ]. The borders of pigmentary lesions usually followed the lines of Blaschko, while neurofibromas typically involved a dermatome or a major peripheral nerve or nerve plexus.",
"   </p>",
"   <p>",
"    More serious complications of NF1 were seen in seven of 124 patients (5.6 percent). These included optic pathway gliomas, pseudoarthrosis, plexiform neurofibromas, and learning difficulties. Lisch nodules were rare.",
"   </p>",
"   <p>",
"    When an adult with localized NF1 has a child with generalized NF1, the mechanism is thought to be mosaicism within both somatic and gonadal tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131,134\">",
"     131,134",
"    </a>",
"    ]. The risk of having a child with generalized NF1 is substantially reduced for patients with segmental disease (0 to 50 percent) compared to generalized disease (50 percent), but it is not possible to quantify a precise risk. Animal studies suggest that the risk may be proportional to the percentage of body area involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15184209\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Maria Blazo, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/1\">",
"      Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005; 141:71.",
"     </a>",
"    </li>",
"    <li>",
"     Riccardi VM. Neurofibromatosis: Phenotype, natural history, and pathogenesis, Johns Hopkins University Press, Baltimore 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/3\">",
"      North K. Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol 1993; 8:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/4\">",
"      Stephens K, Kayes L, Riccardi VM, et al. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 1992; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/5\">",
"      Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993; 53:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/6\">",
"      Ledbetter DH, Rich DC, O'Connell P, et al. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet 1989; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/7\">",
"      Feldkamp MM, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci 1998; 25:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/8\">",
"      Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 1996; 33:2.",
"     </a>",
"    </li>",
"    <li>",
"     Korf B. International NF1 Genetic Analysis Consortium. Newsletter: Communicated by Dr. Bruce Korf of Harvard Medical School, June, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/10\">",
"      Upadhyaya M, Huson SM, Davies M, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007; 80:140.",
"     </a>",
"    </li>",
"    <li>",
"     Gutmann DH, Collins FS. Neurofibromatosis 1. In: The metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.877.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/12\">",
"      Tonsgard JH, Yelavarthi KK, Cushner S, et al. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997; 73:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/13\">",
"      Kluwe L, Friedrich RE, Peiper M, et al. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat 2003; 22:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/14\">",
"      Upadhyaya M, Spurlock G, Majounie E, et al. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat 2006; 27:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/15\">",
"      Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/16\">",
"      Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999; 89:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/17\">",
"      Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/18\">",
"      Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/19\">",
"      Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008; 135:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/20\">",
"      Staser K, Yang FC, Clapp DW. Mast cells and the neurofibroma microenvironment. Blood 2010; 116:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/21\">",
"      Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/22\">",
"      DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/23\">",
"      Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/24\">",
"      Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/25\">",
"      Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/26\">",
"      Pasmant E, Sabbagh A, Hanna N, et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 2009; 46:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/27\">",
"      Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008; 124:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/28\">",
"      Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/29\">",
"      Korf BR. Diagnostic outcome in children with multiple caf&eacute; au lait spots. Pediatrics 1992; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/30\">",
"      Nunley KS, Gao F, Albers AC, et al. Predictive value of caf&eacute; au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009; 145:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/31\">",
"      Messiaen L, Yao S, Brems H, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 2009; 302:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/32\">",
"      Sheela S, Riccardi VM, Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 1990; 111:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/33\">",
"      Lott IT, Richardson EP Jr. Neuropathological findings and the biology of neurofibromatosis. Adv Neurol 1981; 29:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/34\">",
"      Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet 1996; 66:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/35\">",
"      Hummel T, Anyane-Yeboa A, Mo J, et al. Response of NF1-related plexiform neurofibroma to High-Dose Carboplatin. Pediatr Blood Cancer 2011; 56:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/36\">",
"      Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr 2012; 160:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/37\">",
"      Gutmann DH. Recent insights into neurofibromatosis type 1: clear genetic progress. Arch Neurol 1998; 55:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/38\">",
"      Serletis D, Parkin P, Bouffet E, et al. Massive plexiform neurofibromas in childhood: natural history and management issues. J Neurosurg 2007; 106:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/39\">",
"      Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/40\">",
"      Jakacki RI, Dombi E, Potter DM, et al. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology 2011; 76:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/41\">",
"      Lewis RA, Riccardi VM. Von Recklinghausen neurofibromatosis. Incidence of iris hamartomata. Ophthalmology 1981; 88:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/42\">",
"      Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab 2008; 94:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/43\">",
"      Delucia TA, Yohay K, Widmann RF. Orthopaedic aspects of neurofibromatosis: update. Curr Opin Pediatr 2011; 23:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/44\">",
"      Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999; 84:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/45\">",
"      Stevenson DA, Zhou H, Ashrafi S, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006; 79:143.",
"     </a>",
"    </li>",
"    <li>",
"     Plon SE. The phakomatoses and other neurocutaneous syndromes. In: Oski's pediatrics: Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/47\">",
"      Szudek J, Birch P, Friedman JM. Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet 2000; 37:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/48\">",
"      Clementi M, Milani S, Mammi I, et al. Neurofibromatosis type 1 growth charts. Am J Med Genet 1999; 87:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/49\">",
"      Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer 2013; 108:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/50\">",
"      Airewele GE, Sigurdson AJ, Wiley KJ, et al. Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol 2001; 20:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/51\">",
"      S&oslash;rensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986; 314:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/52\">",
"      Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/53\">",
"      Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984; 91:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/54\">",
"      Gutmann DH, Rasmussen SA, Wolkenstein P, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002; 59:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/55\">",
"      Listernick R, Ferner RE, Piersall L, et al. Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004; 63:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/56\">",
"      Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999; 89:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/57\">",
"      Guillamo JS, Cr&eacute;ange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003; 126:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/58\">",
"      Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989; 114:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/59\">",
"      Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/60\">",
"      Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004; 111:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/61\">",
"      Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/62\">",
"      Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics 2008; 121:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/63\">",
"      Blazo MA, Lewis RA, Chintagumpala MM, et al. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 2004; 127A:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/64\">",
"      Listernick R, Charrow J. Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood. Am J Med Genet A 2004; 127A:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/65\">",
"      Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/66\">",
"      Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001; 131:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/67\">",
"      Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol 2006; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/68\">",
"      Cr&eacute;ange A, Zeller J, Rostaing-Rigattieri S, et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999; 122 ( Pt 3):473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/69\">",
"      Friedman JM, Birch P. An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 1997; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/70\">",
"      Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/71\">",
"      Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol 1992; 16:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/72\">",
"      Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/73\">",
"      Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/74\">",
"      Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/75\">",
"      McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999; 36:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/76\">",
"      Z&ouml;ller ME, Rembeck B, Od&eacute;n A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997; 79:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/77\">",
"      Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007; 109:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/78\">",
"      Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009; 2009:756395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/79\">",
"      Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/80\">",
"      Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 2009; 135:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/81\">",
"      Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/82\">",
"      Warbey VS, Ferner RE, Dunn JT, et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 2009; 36:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/83\">",
"      Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 2010; 116:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/84\">",
"      Sung L, Anderson JR, Arndt C, et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004; 144:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/85\">",
"      Southcott R, Lucraft HH. Association of soft tissue sarcomas other than neurofibrosarcoma with neurofibromatosis. Clin Oncol (R Coll Radiol) 2002; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/86\">",
"      Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/87\">",
"      Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005; 29:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/88\">",
"      Calabuig-Farinas S, Lopez-Guerrero JA, Llombart-Bosch A. The GIST paradigm: how to establish diagnostic and prognostic criteria. Arkh Patol 2011; 73:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/89\">",
"      Vlenterie M, Flucke U, Hofbauer LC, et al. Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am J Med 2013; 126:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/90\">",
"      Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14:4550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/91\">",
"      Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000; 5:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/92\">",
"      Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol 1981; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/93\">",
"      Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/94\">",
"      Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A 2012; 158A:3056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/95\">",
"      Wang X, Levin AM, Smolinski SE, et al. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 2012; 158A:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/96\">",
"      North K. Neurofibromatosis type 1. Am J Med Genet 2000; 97:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/97\">",
"      North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997; 48:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/98\">",
"      Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005; 65:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/99\">",
"      Soucy EA, Gao F, Gutmann DH, Dunn CM. Developmental delays in children with neurofibromatosis type 1. J Child Neurol 2012; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/100\">",
"      Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005; 15:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/101\">",
"      Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008; 300:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/102\">",
"      Acosta MT, Kardel PG, Walsh KS, et al. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011; 45:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/103\">",
"      Cutting LE, Koth CW, Denckla MB. How children with neurofibromatosis type 1 differ from \"typical\" learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/104\">",
"      Kulkantrakorn K, Geller TJ. Seizures in neurofibromatosis 1. Pediatr Neurol 1998; 19:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/105\">",
"      Steen RG, Taylor JS, Langston JW, et al. Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. AJNR Am J Neuroradiol 2001; 22:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/106\">",
"      Sperfeld AD, Hein C, Schr&ouml;der JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002; 125:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/107\">",
"      Drouet A, Wolkenstein P, Lefaucheur JP, et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain 2004; 127:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/108\">",
"      Payne JM, Moharir MD, Webster R, North KN. Brain structure and function in neurofibromatosis type 1: current concepts and future directions. J Neurol Neurosurg Psychiatry 2010; 81:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/109\">",
"      DiPaolo DP, Zimmerman RA, Rorke LB, et al. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995; 195:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/110\">",
"      Rosenbaum T, Engelbrecht V, Kr&ouml;lls W, et al. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev 1999; 21:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/111\">",
"      Van Es S, North KN, McHugh K, De Silva M. MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol 1996; 26:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/112\">",
"      North K, Joy P, Yuille D, et al. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994; 44:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/113\">",
"      Denckla MB, Hofman K, Mazzocco MM, et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 1996; 67:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/114\">",
"      Moore BD 3rd, Slopis JM, Jackson EF, et al. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000; 54:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/115\">",
"      Cutting LE, Koth CW, Burnette CP, et al. Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1. J Child Neurol 2000; 15:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/116\">",
"      Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics 2009; 124:e476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/117\">",
"      Cairns AG, North KN. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 2008; 79:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/118\">",
"      Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005; 64:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/119\">",
"      Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 2000; 14:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/120\">",
"      Lama G, Graziano L, Calabrese E, et al. Blood pressure and cardiovascular involvement in children with neurofibromatosis type1. Pediatr Nephrol 2004; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/121\">",
"      Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001; 68:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/122\">",
"      Z&ouml;ller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in G&ouml;teborg, Sweden. Acta Derm Venereol 1995; 75:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/123\">",
"      L&aacute;zaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994; 331:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/124\">",
"      Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. Am J Hum Genet 1988; 42:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/125\">",
"      Zlotogora J. Germ line mosaicism. Hum Genet 1998; 102:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/126\">",
"      Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/127\">",
"      Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997; 73:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/128\">",
"      Mensink KA, Ketterling RP, Flynn HC, et al. Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature. J Med Genet 2006; 43:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/129\">",
"      Spits C, De Rycke M, Van Ranst N, et al. Preimplantation genetic diagnosis for neurofibromatosis type 1. Mol Hum Reprod 2005; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/130\">",
"      Wolkenstein P, Fr&egrave;che B, Zeller J, Revuz J. Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol 1996; 132:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/131\">",
"      Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001; 56:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/132\">",
"      Listernick R, Mancini AJ, Charrow J. Segmental neurofibromatosis in childhood. Am J Med Genet A 2003; 121A:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/133\">",
"      Tinschert S, Naumann I, Stegmann E, et al. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000; 8:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/50/36650/abstract/134\">",
"      Moss C, Green SH. What is segmental neurofibromatosis? Br J Dermatol 1994; 130:106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2939 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36650=[""].join("\n");
var outline_f35_50_36650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NF1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of tumor formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Caf&eacute;-au-lait spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Freckling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peripheral neurofibromas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Nodular plexiform",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diffuse plexiform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lisch nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pseudoarthrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bone lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Short stature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Scoliosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CNS neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Optic pathway gliomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other CNS neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Prognosis of CNS tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      NEUROLOGIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cognitive deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Specific learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Macrocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Neuroimaging abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - NF-associated bright spots or vacuolation changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Increased brain volume (megalencephaly)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Cerebrovascular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Prenatal testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SEGMENTAL NF1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15184209\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2939|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/9/19601\" title=\"picture 1\">",
"      Plexiform neurofibroma in a child with NF1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/56/12163\" title=\"picture 2\">",
"      Neurofibromata and caf&eacute;-au-lait macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/6/31845\" title=\"picture 3\">",
"      Multiple neurofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/49/2837\" title=\"picture 4\">",
"      Lisch nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/44/10955\" title=\"table 1\">",
"      Diagnostic criteria NF1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/33/39451\" title=\"table 2\">",
"      Features of NF1 by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25943?source=related_link\">",
"      Ambulatory blood pressure monitoring in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/16/39176?source=related_link\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26257?source=related_link\">",
"      Patient information: Neurofibromatosis type 1 (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_50_36651="Bronchoscopic yield in HIV";
var content_f35_50_36651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bronchoscopic yield for various infectious and noninfectious pulmonary diseases associated with HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Bronchial",
"wash/brush/biopsy",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bronchoalveolar",
"lavage",
"       </td>",
"       <td class=\"subtitle2\">",
"        Transbronchial",
"biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCP",
"       </td>",
"       <td>",
"        0-1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine",
"bacteria",
"       </td>",
"       <td>",
"        2-3*",
"       </td>",
"       <td>",
"        2-3*",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathologic",
"fungi",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi's sarcoma",
"       </td>",
"       <td>",
"        0-1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytic or non-specific interstitial pneumonia",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Scale: 0 = very poor; 1 = poor; 2 = moderate; 3 = high; NA = not applicable.",
"     <br>",
"      * Protected brush/BAL with patient off antibiotics.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36651=[""].join("\n");
var outline_f35_50_36651=null;
var title_f35_50_36652="Etiology of dystonia c";
var content_f35_50_36652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Heredogenerative diseases (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        G. Due to a known specific cause (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Cerebral vascular or ischemic injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central pontine myelinolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head trauma and brain surgery (thalamotomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peripheral trauma (with causalgia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electrical injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        IV. Other hyperkinetic syndromes associated with dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A. Tic disorders with dystonic tics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        B. Paroxysmal dyskinesias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal kinesigenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal non-kinesigenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal exertion-induced",
"dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxysmal hypnogenic dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"1\">",
"        C. Hypnogenic dystonia (probably a seizure disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        V. Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        VI. Pseudodystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atlanto-axial subluxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringomyelia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnold-Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trochlear nerve palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibular torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior fossa mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue neck mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital postural torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Congenital Klippel-Feil syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isaacs syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sandiffer's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Satoyoshi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiff-person syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventral hernia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36652=[""].join("\n");
var outline_f35_50_36652=null;
var title_f35_50_36653="Cost of chronic illness";
var content_f35_50_36653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Health care charges and severity of illness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 271px; background-image: url(data:image/gif;base64,R0lGODlhAgIPAcQAAP////8AAICAgAAAAH8AAEBAQMDAwBAQENDQ0FBQUPDw8HBwcLCwsDAwMCAgIGBgYJCQkKCgoODg4D8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAACAg8BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnDMGBgoACp+fCCYIAgKmIqiqIxIQAgydtLWFEQMDBgAGubkFJQwDDg4Ds8LExgASBwcNAwu20tN6zLm7vQ2lJc8ICAMNAN3f4QsDEAAHA6FDBqnv8PHy8/K71Pf4KAX7urwDBwUeSCiRS0TBggAKFui30F4Jd/EcyhAwgYDFixgzatx4cYKAfCBBQjggoSEABA8E/ywMRwLhwQEGYZo0aQLiuwIfaQggEKCnz59Agwr1SSBnyKPSFvrqNwLhCHUKFPxLt07qAQAJlHVrkarGzqFgw/4sirRsLQSfnkFQICCBygHA0gF7MCDVgAcA6NrFiysBMhdddfIUS1goWbOIO5lkUGxAglDfIojK6jiUAsqPRSxQ12AVi8AzvhYeTdRo4tPTIDggAnriYNKjD6OeXUsWa9MxRMMuLJu279+fccPQvVtsb+DIk4tonft18bDHlUunzXy48+dDo0/fniVChMt43VR/QRy7YeHc01dxAIHuOfHoAV83D1S7+vtQdDUosCAum/Hy0QeWffgVuMQBAtSlEv98Xs0nYE8EGiihEeboF95/8XHl4IMRTuhhEApAwABbnq0BoIYPnvfhikcsEE0cJ362oYAdsmgjDg/458Mn7MBi2ympeNaKZz7OAliGMqYYVI03NjnDSO9ItgMu/TDjDDTBDFPMMVoqY+UzLwbXoJL1IenkmTEo9csO1vRjDjpQkTAOOOIM4A2db1LFzgox8jkjfUyiKagKaJFS4g37zMQQUzE16pJMi0o0gk2p4DQmmaUNqukMIUapw0glRQoATY0mBNOjo4paUzyWCoZpppvG6gJla+ag5jVZzbLVU1VNBZVVWGllJ1dmqlCekoHKuik0urSKQ6FqKdDXX3LlpeD/XdbuBcC0wxx56avJKjuoLiQtyANNm4FjSmST5ZLZZe6yk25n3rr6agDhiovmAREk4ABASKh227eY5quvk94h0MyhQ/woRJ/G/mmewQdXXAbEKRybIsUWeziPlBgSTCbHHUu4lC86qoExChpzWGzJN5IiM8NorHxCyzS+DPPOYNhsAs6A6syzhyfXGrK94Ao9tISJNh2miUqXAPTEUS9tNRU+Sy0xdiRfzR28BzwNtcjIVu21egsV8IzZW2RNwtRcs332dsoA0J8ObO2zQCgSwAPyCBDsg44IgRcwOAAMJMDfnnzKDfdzXc+tHIKTJaCDAQCpg1cvKEvtWFYfJZgA/+j+NGBOyhk7vjXkckuuXIW5GIlDVP5Y3gvqIhQjgQTd6s77anRJpjuxZG/cuuvJBe5XDwsQYwrnw0iKKqqKSioCpSqpfi++xyMvbgTm4CVBBO5M1RJMpqaffvUnYO+sa9tH7v1sRcOlw0CiFIS/VOijBYDvvRvA7roVvP8JkHhIK1j35neafTjDgRe6gQAAUgxgTLAA6ngRtkRHOg7WpXSnq1doVlcc+TEQNQewxwIiaAOU7EMAkMmR4a7HlMIdzoYjSNziRAi/e5nwhInB1mVwFwRzPUx7PlwgEBEDuw8eIQI064HbRvC4EipxiWbBIYMSOLIrYvGLYuJi2cBIxv+GITFpZUzjD6a4HBLu5odqjCMA2DhHN8IGjnK8BwK+s8URxs+LeZxGLxDEuJqdUYGBVI873mfI4rkskdMZhST72EM0QjI5VDKA6SjZnD9eMjkOaIADFok3lewQcYrbmwm0CABW6lCVCPRjEj+JnGYZ4G45wBwGsZWNEL7tcx/04Ed6ab9YVhKRtPyNAx7QgAmKrQa064XlCji8EQBwNde0lvAOGEZZWjKZtBFGLkjCg+Y5wBTsawr6XtKodD6EVYfsIjh/gwoI4G9K4UvVLkilPnauT1XvhAcjrePJec6mUKS4nwj4p00DDsR/2cwmNbnZOEfmzKCzudU/7ukVCtr/j5hx2SAwQzdSEBazm8eUJ0YbmBIBOCABB2DhDFyIE3a8MhS9sAcrXZnKQqbOokFb6WlSuJwE4JI1ROQBHav4RkAKNRLOMAAD9mPEIUBxYGI03lMRkyBfJE6mZliqHUmDx61GAiJRPINYC2rWo7hIDmudZVuPkiO4xnOMcw0JlFLxN5XdVat5Bcmtknqxvz4ysPlAqAHSWligUg2x+egUXzlJULlClhq0OunYsnrYy06DWQYYaCM5e1HPfhZzfSNsDChzzpM4rQTwqky7ZGs3zjD2bYYtrWltwS9/AUwHDmhLtwaptxLoJUF4OS62uLUaY3bSsrulRcIW5oOCZMMA/xwVwa981aur5KpOt11OboMaXQPhYnNLOVyp/KkQgJLAfeN9bHlpgQDFFXcHmGuAZQbCOYKs81T/1aeAVyXQ+MZtvrRojNFwgIsCsGOx/rhKK9Exp3BU2G7viRNKn/tNBGvCMTs6Wfl8IRmpRAMZW0Jcl2bxJSw5t7Id9jAmjOqDvsFDAtIKkgiEgb8hjcDHIigSeQzMOhlnYh8NAMh9KQRWKRLZikbGRP1U2wME+NQHcY1xlCkhgV1Msg1ZRuaWLdEAyylgmZQlz1hj49Qx54EpVfWrYw/s5kocYHCjS3OAoFvnSNClAc/oaxrCrNI+S0IBdAnbGwiNV0OfjdGAdf+01yDdWUlbjdK6tfTSME1eTTsCoeF9AWtXMa9DxfZdmJGXbXnIYTF7ehGZpfILgpuV1TDXuNdKbq635RhqbRjGrn51IsDhqR4U5Lu70m539QQsZA+LwDd5clOFzQj+BOG8Aubn9ALszvfCc85FprYidLnkXDojFN3edjvd+1PSdhoJ2KOHvOctAOuJ2wbq6JwOGiyvDK9jwuAlR8Dx5O8r/0zad2zzZyrCkYY7vCMK97SiewC9a7Q4GiZWcTK4tPFlNANMrAZ2oZHA1ITfewf9MdT94jEQIau4xzpmRcyXEQvZ/VrNbCX5mnkTcU0PFgkrxKo3g22EkpO155aOgN//kGBloae00TrP+ckVwWn5JsHobJ56DvqTqGeOdugjPwLWea51HPwczAg/+hLGTpiyTt0BNpezu60edT6X3Qb70TOK7F4EthsH6ZLm+jMsh3ZwQ1kJfocO4B2tptYWfu50vvrO2774uzcW8uGWvNQtD4P6dl3vSeI7ayb/d87TQMGaVcInHiIptBj8ZmnPOuJJr3jTzwDEa3RixVOmsHGuK98HMIUCnpELQbMs9mSf/eZtzwIaVzcXOelFcAXQ11wJw3LWBzEEoAGsF+Nc9A2j/YAq3+cHKNnal9MLDYMraHX/c5+M8naBDT9t5YOf+fpYiqzJo3sH7JLw6uQo3MZu/9fzbZh3eJp3f/hHck40Agx1PgK4bvBnbwdHfyZnf1q2gCkgWdSnVE4UARBQPs2VAHiRfdhnDNfXStxnPje3Zxk4esungSdwdjlwMiroe8vwHr33D7+Hg8NHYiH3fS8YfjEogwShDdtwOTITZKsnAhFwAHvShJPSeqAwZBaodhhIdEZoAs3EBCnhdK0WdkUnftlBfnXWPMV2NGAHdWJHhiqyhSpAg5u1hpFWd0MIhycxM6DnJ0X4MG64JGZYZ6C2hxHTh0X0h2WChynQRPvXM8hHeWuHiGMRiGMGEHXhAF6nVo9YelkohopoEL3AFgA4h09Xh21oiFtoDAWQAHn3eP90WGmnqIBbuACyUHyEmDGSCCsJeIef6A2Ltom114ls+IlL4HooIIXXQ4WvV4EHWH+7qIXEWERO9IO2SAI7GHwnAXzCR3wDYHywd4Wy94yeGI0/4As5sX17w4IiYILBwgApiI7d14J7x4tAkHjjR44k8FY7on7ZFn/u114T2D4G+IqZFov0aIR1lXs5kW4BRj0EyAsDWYqwOIaoaIR71YE7kCAL6V7/CCkBKY+hd5BYlosQQolbJoc4oJGEs4ISRoLtmILsCI/qaCzAeI/CaIrRqFih5gI2SI3dmIPocI09yIOiwI3eyIwE+W4GCY2fyAAC0Dc72QIy4xDGuC1QOIX/rFcCVel9LsiUfliRMlghBuCSR/CFZgSOySeOw0iMMaUNcTZoNVmGkQiWGmhLCamGElmQFCmLRqg2L/UerpiXSrmXIqmBO6hft8gyJMk9c8mXWwhhv4iWkHiTE9mUq0iBcCmZnKiWOKmI3+AL2UWKYbiWMOiY+DdB7kg5kdmMF8iZlYmH5iJamcmaWOiaeqmIXaV/iXkzi+l28+iVRpib+vYDo6ByWjlzQEZzDgOSfGiaStWbJkmOu5clHYdiXvJxLsacheicGQmd+Kh64JCEI3BhF5YnGlZRtBmOdgic3xliACEQ/hWB7zdgARVtmhmMtjmY7SkEKPEWLBGA6eOQ/x9Zn5USl2+Yn3S3n0fgFMoWFdzloN4lLKFWdZG3nuMoBPFGbxoKD5iJYG3xFnEBMMqla9pya1z5mxf6ldyZAxTxcC7KER7RZ4wRLyfxk6dmGammGat2oiHJnmvknQhaoZImMGeZnmlpoaSpooXpYctZjwYKiI25pDpgj3KpoFLzpIlImbdJhCu6hRSaeUjamVwqpXD4pQgYpq+ppD66IxvapvVAS2bqjGi6pWqaokXEcC+apxYRo58Up605p/o5pmsqRUB6SX5am4CaoH1XqIkqpIF0qOq5lHb6o3T5nJW6RJB6pJKapId4qVPKqImUqZMZpGBKmINqqV3KQKK6mf+NWqqL6qksCqpGkKFuSm8dOglOaU/DgaWTGKWn+qmwmpKy2nd4qqcvyqeaYA5JRk5B2JWTSqmpagNUeqCteqabKqaTACzoaIVGOqrVKqem+qwjGawSNKyUcDv+kFTugxO1KlDFaqwPNwHs2q70Kg8F8K7w2nDyWq/8ehP4mq8bsa/92q/3CrAuKrADW68Fa7AOh7C1eqt8gK7oeoysMq8Je7EY+0IYu7EXq7Ec+7H06rEgO7JtKrIke7L0IJt/IHAp2KxjQEdXALNVILMzG51rZLNbsCVZcZRI+XWz+bNAq4mIgADPMHEuKwY0izU462R4KbSckLRSALVRu7RKRbX/VSuamCC1UKC1W2u1U+q1X4u1l4CMZ0C2ZQuxX2C2ZqC2ZMC2Vvq2cBu3cju3dFu3dnu3eJu3eru3fNu3fgsJTukQAqBeXhAi+/AAaFsF7iAlrcACC0EDkAkFiytzw/RBj0sCl1uzptA3iTsoDcYK2AIGP0iLrdgzuYBuDJp/NJB6TdBVqAsTozAQmSsCszsFuRAOvQC2ZaEA6jAQdLELM+oAktEfiRNa0YAAM+QE2fBgrvUP0RA4ptAfUeEemcEfgYM4xSC8DQN9vIMQEVAM9IJhzYA+E6QudlMAibNH+fYY5gAQplC+4cuAddG9MIG8knG57asOV+ALIfhBYPMi/wFRa8JHvcuIH3QBJ6vxDYj7DAqwEgVAtOtgDp0LBLx7u6oUVXThjlhCJzDFANv6Cw98F5r0b9JYAJioFDWaAAbwLyq4wDCxfSLiDKmyH3tEPm+CC8EFC+fAADJ8dXBxwtZluS8sws+wv2rDLx+UKwmCDs6bFdh3AB6cnSvyDXD3HgmyH8UQWujDa9/bXE8gAQ/QGNowDGrzQcQgDJLxD/wADMV0xSYcf1jWjcVXEAmyC3W8EKibKg4EKT8GU9CXEHGRNruEeHJcyP7wEY+Lx6lixNL3QcVkP4/MxkrGuh6SvQe0ffXGI5lrFYDpBLsTZLnwDSr8CQNxOv92AKO0Df/FhMmkUMASpAswlT7bNwvmgLz/9ri5klCZi8po4chxkctuK41jeRVBjMiQksdWYD/u8REyLBWWE8npkMqRyyLbh3tWQrpaTALuEZrg6RZZEQ3PkBJuUaOhezoC8ADPHBfXLADa8DCMoj/OMEHh0BfponEC0DyLrF0IshDMjCAIgAz37MVi984wkbuLTM/6m8zAYA0fYQ4L8F3QbM7o3CQNXAAOIQFctzdHxWuj2AQhojgJICWGGxCrkCMO0S+rOAvotwwZ7co2EAEPPAL7wAo5Aksq8QAJaQAyhA5Hhbw4UQCSwQD7wF87rQQw7Rkzbb/nuxwBcZdUgH6BIyXKYyT/6Id+KL08MJPBfzs3q7jVXv3VYB3WYj3WZH09xAcMiBYv0Hu+00uj1gsMtmy0ZS0dqCxVJQjF6CgM0cDBeL3BcAEMGFw3c60cz+B/s6DGafM/VZzGk8zGcSF9Zay7g10IsGB+dlLX22DKoYDZEFZMokwK3DzZsxFT7EwSEm05nxkepw3I43kXHyrayXO4q3DVRmLSI0DboxImI/0AUQnbvv3bwB3cwj3cxF3cxn3cyJ3cyr3czN3czr0iTtmkNXDUEjTTKbDSNYDdPnA31E0C3f3cNPCDkZ1LT5nPMdAXSELJucGzZlfQ5X257hDa4M0VLvbPy5AjvN1KOTG4oqAS/8vDuQxAPk+5wnVhALGwHISrQ+gQKohLAiPNxIYTEKFAfaggCv2R333DAP2x31Ki0yRNAhid0qiUvO7AADliJELtL+7dZcWQyeWtABe+ubKw4fN9AlSCE5sbz81gLXeCF0nGznYySHBRx08IFxFAFz1OAtfn0AgAvn+zEC5CzOBQDHjxDwXx40nWZb+gDmkMDNmQPQ7YDOeMvo7h0HOkxrkgAcLQTMVw5gZQ5EBdx+KAIFnOObvE3s1dvsW3fSnREL2wANu3WEOuF3++HItCQy7ybOv4b0nm5tYYugNhP1LBxizxDSd2DgYtDB9hP1mBP/e0fVIiAVkRCo0u5xLc6f+LLOeXW8eWrmL9+xGaXuOwxQrm7NqpMBChJErp+g6f4ESqvsX/EkolcLmPK+eT0oCszdrFZNC5y+y+bN6/5BDEDhNyfsfoU+yH7ubOXm8fZNCyTkVArdN1QQ4McEvR+8fpwC8GTj6+vigM8L65QLiYnILG/hRQPFXJDsn+UddZ0cuVu+nAwOcQ8WPh2S/zDmLVrgsaOaOOvhDvLuf8HuTdjuyyrsXDkBNTdbstl+aswFrl3u7Aqw4LfromkC6ZUe8dvybQfFIQrL3bnuwu9Q82l/EfZPIT3g913MBd4ug8fA5y3vKS8fLfvgTC0GRDrxxZMcFHv/RM3/RO//RQH/UXUj/1VF/1Vn/1WJ/1Wr/1XN/1Xl/jIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gay JC, Muldoon JH, Neff JM, Wing LJ. Profiling the health service needs of populations: description and uses of the NACHRI Classification of Congenital and Chronic Health Conditions. Pediatr Ann 1997; 26:655.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36653=[""].join("\n");
var outline_f35_50_36653=null;
var title_f35_50_36654="EOX for advanced esophagogastric cancer";
var content_f35_50_36654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epirubicin, oxaliplatin, and capecitabine (EOX) for advanced esophagogastric cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Epirubicin",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer into a free flowing IV solution with normal saline*, generally over 3 to 20 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        130 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W) and administer over two hours*.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Capecitabine",
"        </strong>",
"       </td>",
"       <td>",
"        625 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per dose by mouth",
"       </td>",
"       <td>",
"        Twice daily; take with water within 30 minutes after a meal.",
"       </td>",
"       <td>",
"        Days 1 through 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Epirubicin plus oxaliplatin: MODERATE; oral capecitabine alone: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen for prophylaxis of infusion reactions with this regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Epirubicin is a vesicant; oxaliplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of febrile neutropenia with the EOX regimen was 10 percent in two trials",
"        <sup>",
"         [1,2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Lower starting doses of capecitabine and oxaliplatin may be needed in patients with renal impairment",
"        <sup>",
"         [3,4]",
"        </sup>",
"        . Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment",
"        <sup>",
"         [5]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines). In the original EOX protocol, patients were excluded from receiving epirubicin if their LVEF was below the normal range",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count on day 1 prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel including creatinine and liver function tests once per cycle on day 1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for stomatitis, diarrhea, and palmar-plantar erythrodysesthesias during therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative epirubicin dose. Reassess LVEF periodically during EOX therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Hold epirubicin until the platelets are &ge;100,000 per mm",
"        <sup>",
"         3",
"        </sup>",
"        , and the absolute neutrophil count is &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        . In the original EOX protocol, day 1 epirubicin doses were delayed until the platelet count was &ge;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the total white blood cell count was &ge;2000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [2]",
"        </sup>",
"        . The dose of epirubicin was reduced by 25 percent for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. Oxaliplatin was delayed by one week if the neutrophil count was &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or the platelet count was &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . After recovery from grade 2 to 4 thrombocytopenia or grade 3 or 4 neutropenia, the dose of oxaliplatin was reduced to 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . There were no dose reductions for capecitabine based on blood counts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis, diarrhea, nausea and vomiting:",
"        </strong>",
"        In the original protocol, capecitabine was stopped if patents developed grade 2 to 3 stomatitis, diarrhea, or nausea and vomiting",
"        <sup>",
"         [2]",
"        </sup>",
"        . If grade 3 toxicity was controlled adequately within two days, capecitabine was continued at full dose after resolution of grade 2 toxicity. If grade 2 toxicity recurred, the dose was reduced by 25 percent; a third time, by 50 percent, and after the fourth episode, treatment was discontinued. If grade 3 toxicity took longer than two days to resolve, the capecitabine dose for the next cycle was reduced by 25 percent; if grade 3 toxicity recurred, the dose was reduced by 50 percent, and if it recurred again, the drug was discontinued. For grade 4 mucositis, diarrhea, or nausea or vomiting, the drug was either discontinued or the dose reduced by 50 percent. For persistent grade 3 to 4 diarrhea or stomatitis after appropriate capecitabine reduction, the dose of oxaliplatin was reduced to 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . Doses of capecitabine that are omitted for toxicity are not replaced or restored. Instead, the patient should resume the planned treatment cycles at the modified dose",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each oxaliplatin infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\". In the original protocol, oxaliplatin was delayed for one week for persistent grade 1 or worse neuropathy",
"        <sup>",
"         [2]",
"        </sup>",
"        . After recovery of persisting grade 1 to 2 neuropathy between cycles, or for any grade 3 to 4 neuropathy lasting for 7 to 14 days, the dose of oxaliplatin was reduced to 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . Omit oxaliplatin for persistent grade 3 to 4 neuropathy lasting longer than 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesias:",
"        </strong>",
"        In the original trial, capecitabine was withheld for grade 2 or higher palmar-plantar erythrodysesthesias until resolution and the subsequent doses reduced by 15 percent for grade 2, 30 percent for grade 3, and 50 percent for grade 4 toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Hold epirubicin until all non-hematologic toxicity resolves to &le;grade 1",
"        <sup>",
"         [5]",
"        </sup>",
"        . Reduce epirubicin dose by 25 percent for any grade 3/4 non-hematologic toxicity in previous cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline, and a D5W flush is recommended prior to starting the drug infusion.",
"     <br/>",
"     &Delta; Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cunningham D, et al. N Engl J Med 2008; 358:36.",
"      </li>",
"      <li>",
"       Sumpter K, et al. Br J Cancer 2005; 92:1976.",
"      </li>",
"      <li>",
"       Xeloda (capecitabine) tablet, film-coated. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Ellence (epirubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36654=[""].join("\n");
var outline_f35_50_36654=null;
var title_f35_50_36655="Sternal wiring";
var content_f35_50_36655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sternal wiring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 333px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFNATYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKQ57UALRRRQAUUUUAFFFISQfagBaKz9V1iy0qIyXs6Rr6Z5P4VzA+IFtM7LZ2VxMB/Eflp2Fc7eiuQi8YSuFJ0uXB9GpX8c2UVzHaXEMkV7KCYoTzvx70rBc66iuMuPF92H2w6YRx1c55/CqFz401aHG20tWJ7bW/wDiqdguehUVxWkeO4Zgq6nbtbOTjcPu12ME8dxGskLq6NyCpzSC5JRRRQMKKTn2peaACijmjmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACjNFHegBCfbNRzShBjvVfUrsWke/IGK5m919Ip97nevt0FFgOmW5MUbMwLewpg1iyDBZJhGx7PxXIXPiWKRtkJUE9yaxL6Y3bNuP8AUGqsB6xHIki7kZWU9wc07NeMyPeWoUQXc0C9hG2BU0t3qzxOH1GcqwGBv60coHqGo6xZaepNzOoP90cmuU1DxXd3xMWkW5jQj/XOMn8K4+2V4r1J3JlYAFhIdwNd9YRxygOigKQDgDgUconsYdvoT3pEuoM0shOWLc1vQ6NbWyARR/Njpjir9xNFaWM91Kp8qFC7bRkkAZrzWD46eEJziRryFs4AaFhnFLXoI9Kt7NCq7U+XGenWuI8ZWSj4h+E5FAz+9QgdxxXEfFb4zm10rTm8F3Ki4kYtI7xAkKO2D9a4CP46ale65o99q2m2rSWTEM8OVLg9eDmnyNa3A+q2t4ggdcA+mKy7uwinlLFVBxXLH4t+F1sIZLi7+ztIobYVyV9qdafFHwdO3/IatlJGfn4oAs3+lDy3UYbPYVQ0m7v9BkZrSR2i/ijc5XHtW/pGuaXr6NPo13DdxKSrNGcgGo7+3V88AZ9adgNnR/G+n3zrFcK9tKePm5BP1rqY3WRAyMGU8gjvXiWreXbt5CoC5GTnkYqGz1vUbKVVs7yaFT/CWytLlHc91pCwUZYgD3rxh/GevP8Au2uwue4QVWm1PUJo2ae6mlJ5+Zzj8qHGwXPaZbyFAcSKzegOaqm9YsCpGK8e0nU57ecSLkAHlR0Neg6XqcN6qlCqOeCmaTQJnVWtz5xIIwRVisSCQxE5PzA9q0ra5Ep285+lIZZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMPxbZ3N1p7GzXdKo+7614H4i1y90rUBFco8WX5SQYr6YNZWuaBpetQGLUrKGcHuy8j8ad9LCZ89DW4J1VBgSHnI6CtCx1BigKMHZeCRW74g+CAaVpvD+qyQZyRDMSVH0xXD3Pg/xr4bY+dZNNbg/wCsgxJ+OBzVXukJaXZ1U+qF/L8xDtFaEV5FKBhh0rzr/hIngn8vU1ZCvBEgwc1eh16F93lyqRjgCm97AvhuegRTwbxnDAcGup8M3wMDREcocfhXjek6g7MvznliTk12Og6o0OoMzSBlZRgCiW4dD1mB0aJg6hgcgg9PxrIudG0eb5ZNLs3XGMGFcD9Kktb0yxfux1HNSWrBnxKeR2qQOb1LwB4SvyGn0O1D9tq4ryD4n/B6zbVdNtvC0a21xeMw2OTtyO1fRM6/3uB2Nch4nMieINBuVYP5FwR9MiqUtAPknxD4Y8S+D3L6pZSRRK+wSld0bfj7113wq1fTvEfiez0fV/DmnTCZSonijKspAzk9q+n9T0Ww8RWEtrrSJeW0xDGLsMe4rE8H/DfQfCGp3l9pMPlyTnaPMJYRj0GeafN2A1fD3hzTdAtZbXTLWK2jclyEGNxNS3SKFA9PStSUpHFyAD7Vz+p38cKN71I0cjdBJLq4Z32ndsBJ6VWjjZgN+Gx04pkt+kXmGVcqzFi3pWfea1FEhZSD9aCe5dEIWcdwfWrUxTy9pxk/pXIt4gjc+YjYK8cVn3muGfKorYB5bPen1uD6I7u1/wBf+7kRQByTVmS7hsZRMtwS45wtcHpcWs6lJt0yxupGb5cqpC/ia7/w18LdRvHWfX7o26DpDEck/U0rj6nT2mutdW0OzLO3oOc12WjwTJCHuOGPQVV0LwxpujoBbQ7mH8bnJrcqWygooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQXMpiGe1T1RumRywZselAEtvdrLweDVmsBX8t8EZXuR2qR9RktF3Aedb+ufmp2A26K4sfEXR0uPJu1ubZs4zJHxXS6frOnaioayvYJs9lcZ/KkBDqvh3R9WUrqOnW1wD/fQVw2q/BfwzdsXsvtFg5/54vx+VenUUAeBap8GdZ04PJompx3YzkJKNrfnXNXC6zot79l1uya1lA4mYZRvxr6iqhrWkWWs2MlpqMCTQuMfMOR7incGeSeGdedJkiaRXBUZ56V3a6jCg3M+eOg714p4tSy8FeKjYvfoigAorNzsPTNdPoPinTbnaovrZzjIy1W9CT0hXlvVyB5cHoe9ZOtiKLU9Eh2j57jp+FUNU8Y2Gi6PcahcTCaOFN3lxn5iemK4a/8Aibomta14duFley2uWlSUYC9AMkcVcKM5RcktAuew3KKjGS2OMHJWq8mrguUkj2OD0xx+dY412znVTBeW8iseGSUHNZmo6rbrKBLdwjnqZBWbTW6A19W1ZQoCjnOThq848Q6tcLLI7EhCx71L4n1S2jiZre+gd+pHmir3wy8MweL5X1HUHWSxgcARq2dze/tSA47TbDX/ABB51vpthO2WyHxtUj6muu0j4N6zc2w/tPUorXdyUQb2H9K92treG2iWK3jSONRgKowAKlpcw1oeWaT8FtCtGD3tzdXb9+dg/IV12l+BvDumEG20yAuP4nG410tFK4xkUMcKhYo1RR2UYp9IzBQSxAHqaqSapYxsFe6iDE4xuzQBcpryKgyxAqpLfAOVjGRjhqy7y6YN8zZJ9e1AGo93++AH3atROHXIrnYpjOcDOR3PStmwYlCDQBcooooAKKKKACiiigAooooAKKKKACiiigCOUlYztGTXKa1dPFN83FdfVO/063vk23CZ9CODQgOGGrs7hCrBsZ470ms6sUtVijbaW+8BTde8MX1hKZ7GQzwt1XHK1wmo6mryyAzANHwwPUVV+xLN+6hiu423Qo5wMcdayLrSomULGj28gOQ0RIP6VUsfEEfnhd+V6E5rcfVYMdV6dTTt3E3Yy4tc8V6E+LS8a5gB/wBXON3FdNpvxUu1KpqejngfM8T/ANDVNby3nj5dFyBjFU7qO3MsiRsDIcfSjluPY7eL4naCQnnm5hLf3o84/Krq/EHw6w+S9djjO0RNn+VebXFrbywASRple9SWjWcZjVY4ycck9RRyodxfiNJ4d8b3FvH/AGa8kiOM3LLtJHpT9P8AhR4dSGNhbyo5XGUk5qSYxrlk2bgQcdMc16FpTpNBEQcZAOR9OlD2EcVJ8KtMuIWiEl2Y2GCrSZB/SuG8a/Bywt206HS5JRPcSNH+9bKjv2r6GhkToScj3rkvF1wf7e8OKMFGum3e/Ap060qewrHzvH8HfFUUqxs8cUfnYIjuCu1f7wFd1dfCLRnhj86S9d0A3Eynk17SVSTICjOOpHNZ18qpE/yk4HIBrSdZ1Olh2PCtU+F3h2GTCJcrIfu5kPNer/D7W/DXhTw9BpiRvYlPv7lLb29cis692NqIaRVZQpwCcYqCeCCeBS0QwD165rKwbHo0XjTw/KMrqMf4qw/pSv4y0IDK36P7Kp/wrzeG1s2iby448jgg96RbGCJ87FyecChRC52Vz8Q7QSFLSyuZW9WG0Vl3vjPWZM/Z4YbdT0ypYisuSKIIXQYb1qKGUSR4yTjjmjlsFyO91bUr7ct1dTOPTOBWcskisock7TkHNPuLgRbicCMH161m3GoxTL8mR+lFgueq6XqAu9PidGHC7Wwe9Q3U6b9pbJNee+EdbjiuJbORmy3KgHvXY2em3+qyr5KFIc/M7dh7UOIXNbT74K+w4I6YFdXZIQu7pntVDRtBttOUNzJL3LdK2ccVBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAZ5oxzUBkaN8EFgamBB6GgAIzXE+MPhvpHiHzJU32d4w/1sXAJ9x3rt6KAPnPVvhT4j0ti9kUv41JI2NhmH0rmprbXLOYi90m+Xb0wuQTX1jSEA9QDVcwrI+R5NXu4ZiHtbqAjGdyHA+lWZvEcaBfMMqtjr0Jr6omsrWc5ntoZD/txg/wA6y9Q8I6BqAxd6TaP9Iwv8qLi5T5wtvEqMuZJiF9CaiuvFlvCFEILt3Oe1e7zfCnwfKxY6UBnssjAfzqew+GXhKyffFpETN/00Jb+ZouFjwCDxbFLKTcSuFY4GBwK9p8F38VxYRoszYwDg10d/4O0BtLuIE0mzRShIKxAEHHXNed+EpRaTyQrGPKViu/PvQncWqPSJLgRqAO/euZ8SENrWgMc8XB4/CtczCQYYYAHy1zXi+/tbC90W6vJRDEtxgu7YA4oSuM7RTtUlhjntVe72iNmA5xxkdaZbX0FyiyWciTIRwysCDVXUZ3+zyMwHHGBRswueZeKtUMGoSSBlVWUjg9DXKN4ncSshutqjgA112k6XZ6946t7W9UmIsWKZxnAzXrNx4C8MXCBZdGtTgYyAQaqUh2PAo/Ebx/Mhzz1Jqy/iRpmXY5STHavXJ/hL4WkfcltNFznCynFNX4S+GQwbyrg/9tT/AEpOSCx5UviZkifznAxWfdeKGt+IJUc55Ga9yt/hn4Xg3YsC+f8AnpIx/rV2DwD4YhJKaPbZPOSCf5mlcVj5wn1ebUI/kVi7nACZP6VraD4O8Tavt8qzkEBPLSnaMV9F2Xh3SLFw9rptrG/94RjNagUDpwKHIdjznwd8MrXR7xb6/l8+5A4QfdX/ABr0VFCAKoUL6AYp1FSFgI4xmikdlRcsQBVO4u+SifnQMug5oHNU7OQtkE5q4KACiiigAooooAKKKKACiiigAprttUmnVXvFZoG2UAZ010d1MN2VbMbYbvmsi8umjkxnaBUJugzgqcjuc07AddbXqyACT5W/Q1aVlb7pB+lcZqWrC3sVSQE7228HtXNXaXEKNcaZqc0Lf3C3H5U7Cues0V5nY+L9YtlAuYoryJVGSPlate2+IWnED7bBcW57nbuH6VNgudrRXMp458Psu5r9UH+2NtTDxl4fK7l1O3Yf7LZosM6CiuSufiBoMGVW5aVx2RCaxr74gzTAjTbMKP78hz+lArmx8U7m5g8IXUenX32K+mwkMmM89x+VeCabovxAtNskOoW1zE2TtKgHPrXb3b32qX63OoXDSsDlVz8q/hXaaVZF4kY8IRV2sG6uebQ3vju3iCvaiVB1ZSP8K5H4mJ4i8S6dYWGpafLAVucqQc7sivoU2zQxliN8P92ud1+OGXW9ABG8Cctj0OKaYj5AtNX8QeFb54bW7vbGSNuY9xUH8Oleix/F7xPfW8NrHLYef8oUyJhif5V7prvhTQdduhJf6VFc3bALvYdhXlfir4COFuLnQ77BLbhDIOAfQGno9mBT0LUPG0HiSz1C5is4mVxvl/2Sea+s7WUTW0UisrhlB3L0NfHfg/RfE1lrSWGpJJDbn5WDsSpA44z0r1/SPEOp+FVFuh+0WYPEcnOPoaiW+g0e1UVxelfEPSbpV+2F7Nz18wcfnXRWuu6XdJut7+3cezipGaVFQLd2zDIuIj/wMVHcahZWsZknuoUT1ZxQBborkr7x/oVsWSK5NzIP4YRu/Wse++I4QE21g2PVzzRYLnotQXFwIcDGSa8y0/xveXF9tvJlW3k4AVcYP1rozqI3Aq2fQ+tNIDWu7vcjGQ4HpVL+0UYYQZY1h6heyOeGx9KdbuvlhwxB7CiwrnTaZcMZeRW4DkVgaNFLIVYgqh5JrfAwMUhhRRRQAUUUUAFFFFABRRRQAUUUUAc/4h0b7Tbs9vhZRyR2rzy6nayuDC52uvY17EwBGD0rA8R+GbTWI2Yjy7gKdjrxz700wPKNQ1p5GXyjmNDgZPWrltMt1GN5ZWPPBrgvEdrqPh3U3sNQGAhLLIeAwJrS0rV1EMbJMrHuMVT20IbPQIEh2FgOgxx3qhdwwyK2ExnmsWLWhKpUMFx2zUFzrwS33MyrgkLg5px7A32LiWkM5ZHX5T61b+w2lsiBI1HqcVzEWvDOXniTA5zWdqfilQMJIp54IJoe9gudZIIo5HdMMo6Cqd1qsUI2gYwc8GuHTXnmm2wyMzNxtAJrR03w94h1iR1tNNupN38TrtA/Gh23FqdhZamjtvZifTNeo6LIJbGEgZO3pXjF34V8ReHY7ebV7dRaZALxuGwffFeo+H53ezhEasWPQjp0pJ3Vyzo57hICCxA/2a5HxVAX1bRLoARr9qA69cjvXRCNVctL87jqT0riPG3jjSIPEmm6FJcBLqKdJ5nk+WONcf3j3pxhKXwoR3CTLbssUq7CBjcBxVmR1+zF1IINVbC8stXgN1aTR3Nu3CyIQyg0jwvDlUB8v0JqUrOzQziNVEf9tiV+i81m31/GHEbOhzz70zx7cTLNttYi0rNgKp5b2rmb7wj4xhP2yXTJWT7y+WQxx9BVNK5N7s35BazqSSBtHOals9HtjGrKeq/nXn0uq3VlKRfW8sEmfuyKVrXh8TIBEsLsQBn0ANDQm2dV/Y6LLhXIA7BjViTTIfJ+Zs+xrK0rXDJuJPzA8Van1VndcADueKduo7luDToMiRY9oAweKr3QC5UEFs+tTDUhFBukywPWsq71CCa4Yqm0gfKaUbbhdsmmj2RDcAM+ldD4b1Fb3TpIm+9EcZPWuB1TUygcISWAAAA71p/DS01HVtcMdsWFvkmVyOFp7CTvI7mNGluGig3tJ2Wuu0Lw+0EYkv23v12dhWrpGj2+nJlQHmPVz1rSrO5dhsaqqAKNoA4FOo6UUhhRRRQAUUUUAFFFFABRRRQAUZoPSoQ21+elAE1FAORRQBl6/oGm6/aNbapbJNGRjJHI+hry3UPgoqXDPo+rPDGekcq7gPxr2aincLHga/BzxEjvt1Wz2tkZO7/CoF+CfiIyEPrVp5Z9mP8ASvoOii4rHiWmfAmFWDanrMspzkrGmB9OtdVpvwg8J2ZVns5Lhx1Mz5B/CvQ6KLhYx7Dwxomnqos9LtYgvTEYrXVVQYUBR6AUtNd1QEscAc5NIZwnxsjupvAd1Hp96tpcM6bSy7t/I4ryjQLH4jwQL5WoWskJ5AHBr0DxjqS+I9ZisrJ/NsYCd7L0Z66bR7RLezjUKfu4NWtiWcBbnx0iASRxTEdQGAya83+KPhDxHq2sWVz9iWK6uWEbOXHznHHSvo1wI2BTv71zni2Tzdc8N2xJybhpOORwB/jVQqSpv3QPAtJsfiL4OMs+n2V1DGDtIX50YkfeC11ujeJfitrWmR3VvYWXkMOHkG0t74r3OL7uMgnH1/SmmAKm1cIg4AAxitKld1F7y1C1jwe3l8cJ4l0qTV4tOgjNygduuBnmvqFOUByDx1FeN/EGwE0L4dwy/Mrd8iu6+HviOLXNFhV3AvYl2yJ344zWDWgI3NT0bTtTjKX9lBOp4+dAa4PVfgz4YvHaS2W4s3br5T8flXpY56UVJVjxS5+DN5blP7K1obVHSVMZ/KsK5+HHjOzaUwrBcjPGyTr+dfRFFO4rHzLN4d8bKjRS6TOec5Ugj+dRReEPGVyxVNLmVgP4yB/Wvp+ii9gSsfPWi/CPxFeXCtrFzDawdSqtuc17f4a0Gy8P6alpYRgKPvN3Y+prWoobuCVgoopCwAJPAHekMSRlRSzHAFVEuTJJwMLVe9kaYE5xEP1qG0uELhRnjinYLm0pyKWmxn5eKdSAKKKKACiiigAoooPSgBrsqDLHFVfMLSccj0qPVZTHHz09qwW1iOJtuefWgDbv7xrZGnX5gBwnrWDZ+ObUybNQgktucbyMis7U9dSWaONCCB15qlfSQToMwRFivHrVcpNz0ayvra9iWS1njlU8jaefyqzXhkNjPaXH2nTp7iGYHO1G4/Kt6y8favYME1OyW5QcbkOG/GlYdz1WivOW+Jo2My6PPgesg/wqEfEm7uMi20nae2980WC56ZVe8vbWzQtdXEUK/wC2wFeWal4u168HlwslqCOTEvI/Oucm0ma8l8++vZ53/wCmrZH5UJA3Y9B8QfEnT7ItFpkUl9N2ZRhAfqa4C817xH4km23FyLeAtnyY+AB9actvEoEe3bjirtusMJ+Tl8dutO1hGt4R09bK+8lQu3Gce9d7EoCDkccYriPCuZ9Xkck/KvNdiXCggdzQAkkBLKV59a5rXk/4q/QgRwokYH/vmulRlWM4Y7c59657xDNGmtaJJJ95pmjB9iB/hQBuRKpOU7051LnGcmo3KrFtUkGnwsiIGbJJoAwPG0IGnSuy/wAHWvONAgvxdx6jau9u65ACnAx7+teoeJ4hNpsu1hux0J7Vw+mOYrdI4+V5zk00wOl0n4hXcUgj1az3xg482Lr9SK7/AEvV7LVIVks7hHz/AA5ww/CvJkWONCZDyx4AFVGs389poJngdeQyMVNDiF7HudFeUab4s1ywaOOd4ryIDB3jDfnW/H8QbaPaL6zliJ7o26pasNO53FFcvB450OYf6+SP/fTFOl8caCisVvfMYfwopzSGdNSMyouWIA9Sa8/v/iCWDDT7MgdBJMcfpXL6lruo6iQs8zuD02Haop2A9d/tG1Z2jinjeQc7QaqXNwZJACcLnHFeVabqn2DULeYYODtcZ5Nd9cXUaxeZu6jcKdgLN/efuii8duKoWU5FwEHPesmeWSV2EbcA81v6FZSSlZMfIOppsk6OyB8sk96sU1FCqAOlOqCkFFFFABRRRQAUjdKWg9KAI5YkmQrIu4EV51430m40yB7izybb7zHqRXpNQXdsl3ayQTDKSKVIPvQgZ81Qa+rXkis+Gc8+1dJb6wv7reMZ+Xd6VieNfhfrmj3E97pi/bbUkudv3lH0rh4tWuQUjuJJEK/eRhgjFUtyHue127w7dwJYA9e1R3UkDy7iFHauOstcAtgY5lVcdD9Ki/tpXkIdlJ65Jp/ZGt2dPetAjJGQuD/WmQ3yW8e1FUjO2uQ1DVPmVjOjcjiqD6+tvlsgEDJBNN7IR2Muo4k2glRu55pl3rKIkgVhxjvXnk2uvdShYVeaRv4I15/StDT/AAj401tW+xaTLHDIf9ZMNoApP4kx9DSvfEixkAtzn+E/zqKfxfFG2Q2HHTBrpNG+BGqTyJJrWpwxKcb44gSfzrq9b+DmgWnhu7bTrKS51NI90TNIcsw7Yzik371xtXsU/hjfvciW5xzJjIJru/tCsRwVweeeK+e/Cmu+KNNkljt/DzOIztb5xkY9sV0sXxC1hWkW60S6hK9cR7hTa5gvY9gkuIwPWud8RXUTatocAuIhKkzSNGWAKjsTXEH4lGJIydOvSzdcw8V4l8R729uvFU2uwSXUUtww8sBSpQKoGM0JWEfYeGPzu2c8dc0158kRjtXyN4L+KOu6TqkJ1DUJrmyz86SHP616jD8Ybi7YtZaF9sHbypeaIu70QHrmpODYzqwGMY5rx6419LO8MOT8hP5VHq3xZvmikSbwnqEAI5+bP9Kd8KNCtviJrF9PeRXFrb26j5SCCST60LZi6l1PESy5UMcjBB9K6Gy1KNrUHcWYrz707Wvgvcwktod+pUnJjkyCfbNcRf8AhvxZoEj/AGjTrl4R0eP5hQ2rIGd9ayrLnA+bPcVJdeUXIlRRjgkV5bY+JJreaRbwSx4P8XBrbh8SRzgFpCB2J702HY7QWsEKlkwRjjNUhCr3GcBOM8DFZcGvwCLcZ1ZewPWm/wBspM4ZJc7uMelJbDe50MiQyQMrAEnJyaySoRT5Z4GOD3qlfan5agiTB9MVTGrxg/vZPfpTfwiRdvZiMKu1W9utdZ4b1EXmlxCd98kfB+leU6nqiLK7RSbgOhBya9K+DmkXuqK97fQtDZAjZuGPMom9hR3O40PSHupGaQFIc5J7n2rsYIUgiCRKFUdqciKiBUACjgAU6szQQnBA9aUUzIZs+lPFABRRRQAUUUUAFI2ccUtQXM3lqaAJlIYZFLWRHcvC+/70R6+orVR1dAyHIIyKAFCqO3tk1xvjL4daH4oTdcQ/ZrodJoBtP4jvXZ0UAfP2ofA7VFnUWOro8IP/AC0HOKdb/A7VmlPn6zCqf7KEmvf6KdwPFbT4D2YP+l61ePnrsAFdDp/wa8J2wBubea8fGMzSHn8BXpOOaKLsLGPo/hjRNGCjTNLtLcr0ZYxu/PrWxRRSAKz9c1W10bTZry8kCRoCee59Ko+IPFOnaMpWWUSXOPlhTkk15Tr97e+JbkSag2yIH91CD8qe/uaaQmw8Hr9ovZrkt/x9SGQgDpzXfJaMI/ugg9zXN+BoES9kjJXjkV38cPQ4yOtXcRj3FvHIoARCR/siuU8T6bb3Gs6IkttG6mZyylRgjAru721H34mCv/drnLiTfr2lLcRGMr5h3N36dKSYHlXiz4D2Oo3b3Oh3YsN4z5LjKbupx6V5TqHg3xR4L1hXWyldkYokkYJRzj25r7CZZXO2FSq92Pf6VIbRfJAbMh65brmrUrPYDyD4ftrGo+F7iXXVO/G2MMOR+ddr8Hbm3srzVNPkCRzSOroem7Gc/wA61763CWz4XAxjgV5fd210NbD2MzQujbxIDzmpeqYup9HUH3ri/CXi9bpIrLVyIb0LjeT8r/j612gIIBByD3rMsxtY8MaLrCMuo6ZazZ6sYwG/Mc1wWtfBPQ7t3fTri5smPRVbco/OvVqKdwsfN2sfA3X4P+QbqMVyM9WO2sGfwF4x0pth0y4mAH34vmFfV9FCYmj49OkeK2lKTaTf+2YTXQeH/hx4s1ggS27WMRPL3AwQPYV9REDuKMU+bSwuU808IfCPRdGZLjUs6jeDktIMID/u16RDDHDGscMapGvAVRgCn0VJVgqvdT+UuFPznpUs0qxRlmrEvptsqM2cnoKANDzsSAA+mauqcrzWJZP5xUng55rbXhQKAFooooAKKKKAA1i6lNsmZZAQOtbVc/4rtJXt/tEOSUxlR6UAKl3FGhlfgAZJPSsUeILqxnMsCC508tllH31rA1LW2a2jtk+8T8w+lQkyOu9XwcfdHer5dRXPTdH1mx1aLfZTq5HVDww/CtGvEGgcXIubN5LW5HO5DjP1rp9M8d39oEi1ix80DjzYDyfqKmwXPR8/X8qXNckfHNj5e5LW7bjONlVD4+3yBINJujnu2AKQXO4BzTZZEiQtK6oo6ljivP77xB4hu5NtnFDZxHqzDcapNaNcxltZ1CW7b+6TwKdgudRqnjXSrJzDDI11P2WFSw/PpXMarr+s6rEyRkWVuw52/eI+tVxcWliCIIAFHfHSsTV9d2xsQ68HjHpTSB7A9vaW5Ds7yTH7zOcn86z5dRjhbJwADgA+lctqnihgJmJ3bcDArO0iw8S+K5ydL0u5dA3+sYbUx9TTE0et+EL61OoI8Z+ZuDmvQkdCMhmGPyrw7RLDWPDesRw65EIWYbkXcCOtev6fMs8a7pEwRnG4VLY0WJ7ppnKwqGxwWrmr/A8Y6RbXD+Y7xSsR6DjpXV/IoDRbQPQV418RPiBaaF8RbKWK2NybOB4pF3YLO2DitadKdR2ihPQ9eijltzlSXixwO/4VKs8bISMrjqCMGuF8OfFTw/q6QJI0lpeSHH2d1Jx+IruryFfs7OMc8hs9aVSnOk/fQzH8SXi29k5DADbXl+m3UMt5JK0u4hug71oeP9ZnDi0t1MkzsEVF6kmuLXwt4u03fdzaPci3PzHGCR+A5pbKwkegyCG5jRdo27uOelbOneItU0Rdp/0m0X+BzyB7GvMNN8RlHEMyMkqnlG4YfUV1sGrxTxNlgwbikkmF9D1PR/GelaidjS+RN3STj9a6RWDKCpBB7ivDooYXjwwGGOeeuK0LG+1LTMPY3bohPEb/ADLj0pNdh3PYqK4az8bSxBRqVm23vJEc/pWvF4z0Nwu69WIntIpX+lSO50VFZ0Wt6XKAY9QtTnp+9FNn1/SoPv39vn0Vwx/SgDTqnf6laWCBruZI89ATyfwrhPEfj6Xd5OhQ5B4M8gwB+FcVcPPdSvcajcvcz+pPT6UWFc9mivFnia5bBj/g5rEvblpJs46HiuQ8Ia15bPY3DMUYZQHtXRwxvczKsOSfSraQrnQ6KrSLkjoc5rcqtYW/2W2WPOT1P1qzUFBRRRQAUHrRQTgUAGRSModSrDKkYIrOlnLOVWrttKJE9x1oA8E+JRbRPGRjTKQSKGXPQ5qfRdYSaEKWUv0616b8QfB1t4t0sxMRFeRjMM2Ohr5w1vTtb8F6iI9ShYQhvlkH3XrS9ydtD1lXBccj86th0zlwBjvXmFl4rWSPDNtZqtReKCm7LbhRoLU9FOrKuETbgHOcdaqXOsSx3AMZUKe+K4K68ShFDR4GRnmq03iiGW2YOT5g754o62DU9Fl1UyRO3n1iXWvpDIcnJ9zXnlz4mkim8qH5s9gc1a07wz4n8UzRCx06ZYieZphtUD1p3QK6NPxD4qCx/JJgemaytHsdf8W3Cw6PbM6E/NIOEUfWvWPCnwS060Mdx4ina/uBz5QOIxXq+nWFpp1usFjbxW8SjAWNcCpchpdzzHwR8HdP0txd69J/aF4edh+4v+NepWtvDawrFbRJFGo4VRgCpqx/E2u22hWJmnYNK3EcWeWNTuUeR/HPQbHWvEVptklivUjw8iSYAHpXPaB4CumU/wBn69MkvQiXkj9a3NQuXv7uS9uctJI2WBHT2qLT9XistSU7toPB+tVsidy5afD/AMSCAqPEhXPqn/164LxH8KdSfxRDZNqsD3WpAuZ2jOUK46c98ivoDSr9biCNlO4GsTxKU/4Tbw3Iv+sHmjH5U1OUfhdgep4nrHwQ8TaZGkun3sd5LwwZW2tvP17VrS/DbxXZ6UJb7xhdQu3JiDk7T6ZzXvxlJLE9VFeZeMNWa71QWytsiT5mOetaTqyqR5ZCtY8j0nQby08Y6f8A2trN1d26ToXOSP4h3r7Ii2mNdnK7Rj6V4VNpkF/GpCrvxkMB1r0vwLrRnsY7G9O25iG1Wb+MVjJWHFlPx38OtN8SRNNbqtpqIGVlQYDH/arw3WfDfiPwdK326Bzb5yLiIb1x7+lfVZqOeCK4iaKeNZI2GCrDINK47HzHpniGN1V2ccHHWuss9TiurdRuxg1ueOPg/p+ph7rQWFld9fL/AIGP9K8e1ay8Q+Ep/J1eznjgB4kUb0P4jpVJ3E1ZHqsNyCSu4MPQ0y58qRMNbowxksa8vtPFTiSNiQBnnBzW7Y+Kopo/LcksRzT3JV2dbElqyIBAqnHUc1BLYxQyNJgc98c1kQa9aLEqs2znqanl1GNyzIwbuPmoshl6YxZ8vduVRniqi3BTIfBTORxWbLrCq2GKqzcZrI1jW1jKlH3KPlO2nbSw9Dori+S1v45ifmDDGOnNe2eFrTbYR3EqgSSDI+lfP/gPRNQ8Za9A7xSJptu4d5jwCB/DX0zBGsUKRxjCKAAPaob6DSH9KKrTy4baO1TxtuXNSMdRRRQAUjgFSD0NLSMNwwelAHPXEyx3O0nhT1q/CzJGLiHDofvLXPa7uiupFJHXvWNqWvTafHFCrZV/9Zg9RTsK56VE6yKHU5U1T1nSLHWbR7XUraOeFhjDDkfSuO0jVZLE/abN2udOc5eNjlo67ixvIb2BZrd1dCOx6fWi1gPKdU+BmizzmTT727tAf4SQwH8qoxfAa2R8nXLgg9R5f/169soouFjySP4GaFsxPf6g7d9rgD+VXrX4K+FYiDKt5Njs8vH6CvTaKVwsczo/gXw5pBBs9LgDj+JxuP610iIsaBY1CqOgUYAp1FAwoJwM1m6prdhpik3U6hv7i8t+VcLrvinUdQBS1AsbEnl25dx9KdhXNrxd40g0tmtNOAuL88HH3U9zXl+q3c15KLm9uWnuCe/QfQVfu2hcFbcHdjJZhya5XUtS+ylUcAE5wR600uomxLzW0ihmEhCk9BnrXO6Cup+KNYmj02Ld5amRic4RRzzWfY2l94r1xdP0pXluGb72OFGeSa+pfAng2y8KeHxYwIrXEi/v5scuSPX0p3sw3ON8C3Mstsu4gFThgD3Fat9CLrxlosp48uObr/wGsLwzC1lq1zatxtlbj05rodRWT/hLdJaM5jEMm4Dv0osBo6vJJAjbHG+vCvGUt6LybUo1ZraJ9shUfdPv7V7Hrc7uCpIVenNVPh9pFtqVtrttfKs0M52MMdAR2o2A4Twpr8d5bJGzEMPSuihnmE4KSNHt5VvSvOvHPhzUfh3quEPmaXI2YZfQehro/D+rC/tOHG8rnrzQtQSsesaF4tVfKttWJEh4E+PlP1rskYOoZSCpGQR3rxizuUdPJmQOPf1rf0XxDc6SwhkJubMdAfvr9Kmw7npNQ3drBeQNDdQxzRN1V1BBqvpmq2mpxeZZzK/crnkfUVepDPOPEHwg8NatI0kMUljIe8Dcfka468+A8sDF9L1onPGJY+fzzXvFFO7Cx83aj8HPFCwgQzWs21v+emCR+VVz8N/GFtIPLsw/y4ysgNfTNFFxWPmeL4b+LbiTEtiUH95pBXY+F/gyElSfxBeeaAd3kR9M+5r2ejFHMxcqKum2FrptoltYwpDCgwFUYp91OIV/2jWX4l8R2ehWxadw05HyRL1NZGh67HqsUkkyGK4HzBWPUUWKNxp1OEz8xrRtv9UK4+a9xchgMDPArrNOcyWqsepo6AWaKKKQBRRVa8lKFQPrQBz3jmyJsTeRsQY8bx7V5PfakLu5O37nQN7V7teIt9p0sR6TIUx15NfLOqXVzpGvXWn3QKiCRgc9CO1UiJO2p3+h6i1nKNpGw8FTyDW7bzXVnL9t0KXGTmS3Jyp/CuB0rVY5olIX347101rdFNskIKHHXNW0Lpc7fT/iFZE+VqkEtpMOvGVreg8T6NMqsmoQc9MtivNFvbe+mJu4lJxjjvVS+s9PYKRCGA5IqeXoVc9kTU7F0DrdwFT33io21nTlbBvYM/74ryOO109bbiEgemKSJrC3cNDbLuxyStTYdz0fUvGWmWiN5DNdS9AsY4P41zl14p1XUI8RrFZRkHOGy9c1NOxRhGgUHoAMVHAxZPm+YjrjrTt1FcJpEtbwzbjNM3V3OTSX7y3CbmYYA61BOoVzv4XrlsVmatqKQ2k2xsDgdaYrkWpaz9hjdcK2B97NcTa2upeLtbj07SYnZ5Dhm6qg9Sal06x1LxdryaXpYYtIf3kuMiNe5Jr6e8E+ErDwrpMdtaRoZyo82fHzOfrTbsCVyr8PPBFh4O0tYrdVkvHH76cjlj6fSuuoorMs8t1S2ax8YXRz8shEgz71M08h8Y6cg+4baQnn3FavxFsmSKLUYVJMZ2yY9K5Gz1S3Pi/TxuBb7E5H50ybGt4juWhhkfaMr61r/Cgebo9zdY/1sxx+FcP4vv5Lkm3tRveQ7VUDrXq/hHTBpPh+0tgoVggZh7nk02x2JfEmg6f4j0ySw1aBZrd+x6qfUV80+J/Dl58N9dZHLyaVM2YJyMhf9k19VVm6/o1nrumS2OowrLBIMEEcr7j3qU7DPBtN1aO6iiaNlYnn5e9bcFzIIS5Jb8Oa4fxNod94C117WUs2myt/o8nt6V0eiaktxYnoMd89fwq7kG7aMRcCa1la1kwOUOM/WumtfGOpWAzqVoLqDOPNh4I9yK41JWjdWQD5jzW9BqYijVZIwynjBptdBp6XO/0fxFp2qqPs1wu8/wAD/Ka1xzXlE8+mTEMkBjcfxq2Dn8Kjlnk48rUr1GHQLK2KnlHc9boryGW41oRho9WuAo9Tk1nz3OuSTEf2xclSM8NgijlC/Q9rkmjiGZJEQf7RxXFeJPHtlbCW20l1ubsDG4H5UNeb39lNcHN5fXUvszk0W1mkAbyEXGcninyk81yF5ZZ9Se6v5WlnY9SelXrHUfst9HKG6EKeex9az7lpBIvk4/2tw5qjqlwtvCzZAYryDVWRN7nqunH+0LxVTBBYdPT1rvoYxFGEXovFedfBa3nn0H+0r05dyY4v90V6OCDnHbis3uaLYWiiikMKzdWkEZHI3YGB+NaVc54ulMAhk4APyk00JmnpzkMV52typrifij8ObfxRbteWP7jU414K/wDLT2NbuhXv2hCnmfOp4BNdNFIJE3D8aGLfQ+NlvbjRbxrS/ikhuYjtKuMcCupsfFMLQKC43Dsa998XeCNE8VR41S0UzAfLMnyuPxrgLv4CaPId1tq+oQN26N/Ojm1HbSxw9l4jgW4y7jOTirlz4ittrEEEjuDWjdfAK+DH7L4iyp7Sx/4VXk+AmtFl2eIbcJ3ARv8ACruua4raFOHxGjR48zK/XpWddeJ1W4WLLbs8H2rq4vgTfFVWbxAAAedkf+Nalr8CbJJC9xrl5JnqAiipuJp3OKh8RwywFvOy4HQ1e03VBOpEbfMa2/FXgDw54Y05YoDcXOozEBC7/dGeSRWPYWsFjFjGAOPrR9kFuyHU7owRnzXIbBNcTbW2o+KNbj03TmZ55uGx0Vc9TVzxRqD3N0LW1Vnlkby0UDPJr3j4ReBIvCejrcXKBtVuVDSuRygP8NO9kEUbHgDwdZ+EtEitYFDXJAM02OXP1rqR0paKgsKDRRQBHNDHNG8cqBkcYYHvXlWq/CqT+3f7W02+kWSNTHFCW+UKSSa9ZoouBxPhjwV9guDdanKLifjaB0Wu2oooAKRhkDjPPIpaKAMPxf4ctPE+hz6ffIDvX5HxyjdiK+aIrS88LeJbnSNU3KyHCMeki9iD3r6zrz34xeEf+Ej8PNc2qZ1GyzLEwHzMO60Ey2OHs5hclV6Y9KvTeYioUBZQe4rzvwtrInmSF8rKvysM8g16TaMJICrDjaOc1r1RK+EqpNC4LHAweeaS6vUQAqwwOOlUNS0x0iaWEsA3bPqaW9+Gfie5RJbK4gkidQ4Bkx1+tLqPsatrqEawlt4ORjBqvLexiYfOoyO1YLeDvG9ijI+ntKvQeU4as+fwz4zLnGlXvI/umhA/iOxkukIPCvgZNZq38fmsC6rnqAaxT4Z8ZmEhdKu8lcH5cVkyeDfGLTv/AMSm9577aL6CW7NvXdait4jsKsw7jrUHhLRr3xpqiIiN9nQ/vJGHAFavg34Q6xf3UU/iNjbWg5Me7Lt/hXuulaZp/h/TxBYwxwRL6Dlj7+ppN9ikhLW2i0bSYLG1UKEXYoAxn3q7YIUhKscnNZbymS589jx91ErVstxhyxySagonooooAKy/Edl9u051Ay6/MK1Kawzx270AzyzTbh7e+G1yrL15xW2niWWK4aaJQbYECRcc59ay/GUJ0q/llK/JNyprndM1CRCwIUq/ODV7kHtNjdxXtsk9uwZGHBqevLdK1G50yX7Rpz+ZbN/rLc9vcV19j4u064izMZIHHVWUn+VS1YpO50dFZMXiPSZPu3sX0NR3XiXT4UJjd5z/AHYlJpDNqub8Q+J4bDMFoVmuuhA5CfWsbWfEF5dRt5bGygwehBdvy6Vw17qEazlIujY3Pjkmna6uF9SXxBdvcF5rmXM7clz0A9BXn3iDVxDbskc25xzxW34h1ALE20dfl5FcpoGjzeKvENvpdsvDvl2/up3qmrRM1q2dn8AvB76tqz+INSRmtbc4gD8h29fwr6Pqhoml2+jaXb2FmgSGFAoAHX3q/UGgUUUUAFFFFABRRRQAUUUUAFFFFABQQCMEZBoooA+bvi54Wbwx4q/tm0QDT7tgxCjAR/StPRr83FrHIjDawFeyeL9Dg8ReH7vT7hAwkQ7c9m7V836ELzSr65028UxzWsmAG7+9OO5Mtj0xBHcQGN0B4x6ZzVvw94hu/Dsht78vc6bnAccmL/61ZWk3X2mMkMAwA/OrsxSQFH4YjnjNXZN6ivax6pY3cF9bJPaSrLEwyGU5qevGrVL+xkE+mXDW7E/MqnKke4rdtPGmrwuUuLSG6A/iQ7T+VRYq56RRXDr46kWINJpU27uFcf1rO1D4h3YUx2+neTK3CtI2cfhSsFzvNX1O10m0a4vZBHGOnqT6CvN9T8Rz6xcb0LRQrzEAevua5bXL3UNRufN1WXziAMKvAH4UsIZRuJIG3GKtRFe56fotyLuCBpG/ecAn3rqbVdsIGc1wPw+mWeIW+35ozkmvQlAAwOgqXuVe4tFFFIAooooA5D4o2L3Phaea3XM1v+8H+73rxbS9WW8QBdoI9DzX0rPGk0LxSqGjcFWB7g18s/Evwff+Ctde8tPMfS53LIy9EyehouJrQ6a0vHt7zzYXwR2J61vw6xHMqy3MIY9Dt4rzDStdjnjDk4I6E9617HW4MndMCemK1a0uRfodbBqNqZpALYbhyKlvNZmEY8mMIP8AZrjbzUIo2EgYIG64OarnxDEMASAg8ewpbDudTPPcXqEs7qevBrHkbbIQSWbNZmn6vIbwKjM0eT3rRviPJ80FWc+lCXQV7HO+LruVUCgEr7dzXtPwP8Lf2ToK6pexj7feLkEjlE9K8x8GeH5fEfie3jcFoI3Dv6ADmvpmGNYYkjjAVFACgdhUyfQqKQ/A54oooqSgooooAKKKKACiiigAooooAKKKKACiiigArxz41eGpYp18RWC/dAW4Udx2Nex1U1OzivrGe2mUMkqlSDTTs7iZ4B4XuhMqsPlJHIrpZJjv5UnI6+lc42kzaFq81rJuwjErz27V01uRc2mCQrEcYrWTTI6kjzhIy23JA71VWTLZDbWzng9qz7q31WQzfZ7aWaOLGdozxWNda1LbuVuLaeNunzRkc/WpA6yTfzsOSxzn2qsR85BbexPU1zI8VRx7VZX+725qOXXdyq6OhHtnijlQze1OQBvkOO2apX2sRW9qFLKz/WuavdfO3y1+Y56kVt+B/AWoeJtRjvLtXg09W3FmyC3sBTurBY9R+D9jKujzX9ym17h/kz12ivQKgsrWKyto7e3ULHGoUAVPWbdykrBRRRSGFFFFACEZIIOMVW1Kwt9Rs3tbyJJYXGGV1z/k1ao60AeI658DI3u3l0TVHt4mORFIu4L9KoQ/AjUCmJtfRTnOVhP+Ne+0U+Zi5UeIJ8DYgEF5rtw4H8MaBc/nmtzTfhT4Z0mJnu47i5EY3s0z8AfhivUioJ5FZ+tWcl/bfZwxWJj8+OpHpRd2sFkeKanpVre6lPPYQpb26jZEqDGVHeq1lpW1nUhjk8AivT28NJFNmMFV/u1o6foMAdWZBxyc1V+oralfwB4ei0ize48vbPP146CutpFAAAHAHFLUblJWCiiigAooooAKKKKACiiigAooooAKKKKACiiigApGGQaWigDgfHmkLcTxXSj97jD4HWuds7cxTKFGR1Oe1erX1ss8eCoNcrc6asMrkjg9KqJDWpDpVzJYXQuQjGGT5XUdveuva1s7yINJbwyowz88YNZuj2v+jgEAj0PetmCMxJtzkfypMpGFc+C/D1zKXm0yBm9sj+VUZPhz4YbdjTgmf7rt/jXX0Ugscbp3w28NWNx50diXcHI3uSBXXwxJDGscSKiKMBVGAKfRQMKKKKACiiigAooooAKKKKACiiigAooooAQqD1FKAB0FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUMttDL99M/iamooAjigji/1a4/E1JRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wire cerclage technique passes wires around the sternum (peristernal) instead of through it (transsternal).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fawzy H, Alhodaib N,&nbsp;Mazer CD, et al. Sternal plating for primary and secondary sternal closure; can it improve sternal stability? J Cardiothorac Surg 2009; 4:19. Copyright &copy; 2009 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_50_36655=[""].join("\n");
var outline_f35_50_36655=null;
